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Haemodialysis (HD) and peritoneal dialysis (PD) are the two common treatments 
for patients with end-stage renal disease (ESRD). These dialysis modalities lead 
to substantial reduction in health-related quality of life (HRQOL), and significant 
increase in healthcare resources utilization. However, formal assessment of 
HRQOL and economic evaluations of these treatments on ESRD patients in 
Singapore is lacking. Therefore, in this project, the effectiveness and cost-
effectiveness of dialysis modalities were assessed in Singaporean ESRD patients.  
 
In the first part of the project, the disease-specific and generic HRQOL 
instruments were validated and compared in these patients.  
 
Firstly, the Kidney Disease Quality of Life 36-Item (KDQOL-36) instrument, 
containing the Medical Outcomes Study 12-Item Short Form (SF-12) and 24 
kidney-specific items, was assessed using data of a cross-sectional survey. The 
disease-specific scales demonstrated desirable construct validity and satisfactory 
reliability; the generic SF-12 showed good criterion validity and acceptable 
reliability.  
 
Secondly, two preference-based HRQOL instruments, the EuroQol 5-dimension 
(EQ-5D) and Short Form 6-dimension (SF-6D), were compared among a sample 
of prevalent dialysis patients. Both measures were valid in ESRD patients; the 
 vii 
 
EQ-5D would lead to more favorable cost-effectiveness results than the SF-6D 
when they are used to quantify health benefits for economic evaluations.  
 
In the second part, the HRQOL, patient survival and cost-effectiveness of 
different dialysis modalities were assessed.  
 
Firstly, the factors influencing patients’ HRQOL were identified using data from 
two cross-sectional surveys of prevalent dialysis patients. The clinical 
characteristics were found to be better predictors of HRQOL than socio-
demographics. The difference in health utility of patients undergoing different 
dialysis modalities measured by the EQ-5D and SF-6D was small.  
 
Secondly, patient survival of HD and PD was compared based on data from a 
single-centre cohort of incident ESRD patients. Patients who initiated dialysis 
with HD experienced better survival than those with PD, although patient survival 
may not differ between the two modalities in young and healthier patients.  
 
Thirdly, a Markov model was constructed to compare the costs and quality-
adjusted life years (QALYs) over a 10-year time horizon of HD and two PD 
modalities, i.e., continuous ambulatory peritoneal dialysis (CAPD) and automated 
peritoneal dialysis (APD) using results in this project and local costs data. In both 
base case (60-year-old non-diabetic patients) and high risk group (60-year-old 
diabetic patients) analyses, CAPD and HD had extended dominance over APD 
 viii 
 
and CAPD seemed to be the cost-effective therapy at a willing-to-pay (WTP) 
threshold of Singapore dollar (S$) 60,000 per QALY. The incremental cost-
effectiveness ratio (ICER) value of HD versus CAPD was S$96,447 per QALY 
for the base case and 106,281 for the high risk group. These findings were robust 
in the sensitivity and scenario analyses.  
 
In conclusion, the disease-specific and generic HRQOL instruments were 
validated and compared in Singaporean ESRD patients and a comprehensive 
assessment of effectiveness and cost-effectiveness of different dialysis modalities 
was carried out, showing CAPD might be the cost-effective choice. These results 
may be used to inform future policy and clinical decision making for dialysis 
services to ensure sustainability of ESRD care in Singapore. 
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End-stage renal disease (ESRD) is a chronic and serious illness with significant 
health consequences and high-cost treatment options. Given the continual global 
growth in ESRD population and limited health care resources for treatments of 
ESRD, it is necessary and important to carry out effectiveness evaluation and 
cost-effectiveness analysis of the renal replacement therapies for ESRD, which 
are the two key themes in this thesis.  
 
1. End-stage renal disease (ESRD) 
1.1. Definition of ESRD and treatments 
End-stage renal disease (ESRD) is the complete or almost complete failure of the 
kidneys which remove waste and excess water from body. ESRD is when the 
kidneys are no longer able to work at a level needed for day-to-day life. The most 
common causes of ESRD worldwide are diabetes and hypertension.  
 
Kidney transplantation (TX) and chronic dialysis are the only treatments for this 
condition. Due to limited availability of organ donors, the majority of ESRD 
patients have to be treated with dialysis for prolonging lives. The global average 
prevalence for dialysis was 215 patients per million population (Letsios 2011), 
although significant regional variations existed. By the year 2010, it was 
estimated that the number of dialysis patients would have reached two million 
(Grassmann, Gioberge et al. 2005). 
 





There are two forms of dialysis, haemodialysis (HD) and peritoneal dialysis (PD). 
HD uses a dialysis machine called “artificial kidney” to remove blood from the 
body and send it across a specific filter with solutions to help remove harmful 
substances, and then return the blood to the body. The doctor needs a way to get 
to the blood in patients’ blood vessels. This is called access. HD is most often 
done in a dialysis specific centre, and this is usually referred to as in-centre HD. 
Patients usually have 3 treatments a week with approximately 4 hours each time. 
HD can be done at home using one of the two schedules: shorter (2-3 hours) at 
least 5-7 days per week; longer, nightly treatments done 3-6 nights/week while 
sleeping, in some countries, such as Canada, Australia and New Zealand. Home-
based HD is rare in Singapore.  
 
Since the 1980s, PD has been a practical and widespread treatment for ESRD. In 
PD, a soft tube called catheter is used to fill the abdomen with a cleansing liquid 
called dialysis solution. The walls of abdominal cavity are lined with a membrane 
called the peritoneum, which allows waste products and extra fluid to pass from 
blood into the dialysis solution. These wastes and fluid then leave the body when 
the dialysis solution is drained. The used solution, containing wastes and extra 
fluid, is then thrown away. The period the dialysis solution is in the abdomen is 
called the dwell time. Different types of PD have different schedules of dialysis 
exchanges. There are two types of PD, continuous ambulatory peritoneal dialysis 
(CAPD) and automated peritoneal dialysis (APD). CAPD does not need a 
machine and the patient can walk around with the dialysis solution in abdomen. 





At the beginning, the patient will drain a fresh bag of dialysis solution into 
abdomen. After 4-6 hours of dwell time, the patient will drain the solution, which 
now contains wastes, into the bag. Repeat with a fresh bag. Typically, 3 or 4 
exchanges during the day and one evening exchange with a long overnight dwell 
time while sleep. APD patients have to be attached to the machine called a cycler 
to fill and drain abdomen for 8-10 hours overnight. Both types of PD patients 
need to have a soft catheter placed in abdomen. The catheter is the tube that 
carries the dialysis solution into and out of abdomen. As soon as the catheter is in 
place, patient can start to receive solution through it, although the patient probably 
will not be in a full schedule of exchanges for a short period of time. This break-
in period lets the patient build up scar tissue that will hold the catheter in place.  
 
Worldwide, there is wide variation in the use of HD and PD. The prevalence of 
PD varies from 80% in Hong Kong, 65% in Mexico, 41.9% in Australia to as low 
as 3.7% in Bulgaria (Shetty and Gokal 2003, Johansen 2011). Such variations in 
utilization cannot be explained simply on medical grounds. Various non-medical 
factors strongly impact on therapy choice, such as financial, reimbursement issues, 
physician biases, time of referral and patient education (Shetty and Gokal 2003).  
 
1.2. ESRD and treatment options in Singapore 
Singapore, a Southeast Asian country, has a multiethnic population, consisting of 
three major ethnic groups, namely, Chinese (74% of total population), Malay 
(13%), and Indian (9%) (Department of Statistics, 2014). The number of prevalent 





dialysis patients increased at an average rate of 7% per year from 1999 to 2012 
according to Singapore Renal Registry Report 2013 (National Registry of 
Diseases Office 2014). By etiology, diabetes and hypertension are the two most 
common causes of ESRD in Singapore. Till end of 2013, there were 5521 
prevalent dialysis patients in the city state and the number of incident and 
prevalent dialysis patients are expected to increase significantly by the projected 
rising prevalence of diabetes and hypertension over the next 40 years (Tan, Chan 
et al. 2005).  
 
The first HD centre was established at Singapore General Hospital (SGH) in 1969 
while the PD programme was started at SGH in 1980 as an alternative to HD. 
Like in many other counties, in-centre HD is the main form of dialysis in 
Singapore. And majority of HD are performed in a dialysis centre organized by 
voluntary welfare organizations, such as National Kidney Foundation (25 centres), 
Kidney Dialysis Foundation (4 centres) and People’ Dialysis Centre (1 centre). 
According to recent Singapore Renal Registry, more than 60% of the incident and 
prevalent dialysis patients in 2013 were undergoing in-centre HD; among PD 
patients, the majority was undergoing CAPD, but there was an increasing 
proportion of incident and prevalent patients on APD over the years. Regarding 
the financing for dialysis, Ministry of Health, Singapore, provides subsidies to 
lower- and middle-income HD and PD patients. Government subsidies are also 
provided for selected immunosuppressive drugs in the public healthcare 
institutions to assist transplanted patients. In addition, patients can use Medisave 





(a national medical savings scheme) and MediShield (a low cost basic medical 
insurance scheme) to pay for dialysis or immunosuppressive drugs after 
government subsidies. Voluntary welfare organizations would provide charity 
assistance to dialysis patients who need further financial assistance. In this thesis, 
HD stands for in-centre HD unless specifically stated. 
 
1.3. Impact of treatment options 
Dialysis is both life-saving and life-altering. It changes a person’s lifestyle 
completely and hence has great impact on his/her physical, mental, and social 
well-being. A growing body of studies have reported that both incident and 
prevalent dialysis patients have much poorer quality of life compared to the 
general population (Merkus, Jager et al. 1997, Walters, Hays et al. 2002). Patients 
on PD were found to have either similar or better quality of life compared to 
patients on HD (Zhang, Cheng et al. 2007, Wu, Cui et al. 2013). But which 
dialysis modality, HD or PD, leads to better survival outcomes is not clear. Some 
studies showed the better outcomes of HD (Termorshuizen, Korevaar et al. 2003, 
Jaar, Coresh et al. 2005, McDonald, Marshall et al. 2009), whereas others 
demonstrated that PD was equivalent to HD (Huang, Cheng et al. 2008, Chang, 
Hsu et al. 2012), or even better for certain subgroups (Heaf, Lokkegaard et al. 
2002, Yeates, Zhu et al. 2012, Kim, Kim et al. 2014). For costs of dialysis, it is 
well recognized that the costs for patients on PD are lower than those for patients 
on HD (Salonen, Reina et al. 2003, Cueto-Manzano and Rojas-Campos 2007, 
Baboolal, McEwan et al. 2008).  





Economic evaluations about the dialysis modalities have been performed in many 
countries. Majority of these studies reported that PD was more cost-effective than 
HD, however, some studies reported the cost-effectiveness of HD (Kirby and 
Vale 2001) or failed to observe any difference between the two dialysis modalities 
(Hooi, Lim et al. 2005, Pacheco, Saffie et al. 2007). The inconsistency may be 
due to the differences in survival patterns and/or costs associated with treatments 
between these countries. In view of these differences, more economic evaluations 
should be performed.   
 
2. Health-related quality of life (HRQOL) 
2.1. Definition of HRQOL 
Health-related quality of life (HRQOL) has become an important component in 
clinical trials, epidemiological investigations, and clinical practice. Although 
there is no formal definition of HRQOL, it is generally accepted that HRQOL is a 
subjective assessment of the impact of disease and treatment such as physical, 
mental, and social domains of functioning and well-being (Revicki, Osoba et al. 
2000).  
 
2.2. HRQOL instruments 
Unlike classical clinical indicators (e.g. blood pressure, biochemical marker etc.), 
HRQOL is an abstract construct and cannot be directly measured objectively. 
Instead, it has to be assessed by using questionnaires to survey the relevant 
subjects. A large number of HRQOL instruments have been developed. 





According to the targeted health condition, HRQOL instruments can be divided 
into generic and disease-specific. Generic HRQOL instruments are intended for 
general use, e.g. the Medical Outcomes Study 36-Item Short Form (SF-36) (John 
E.Ware 1993). On the other hand, disease-specific instruments measure the 
particular issues related to one disease condition, e.g., the Kidney Disease Quality 
of Life 36-Item (KDQOL-36), which was developed for individuals who have 
kidney disease and are on dialysis (Hays, Kallich et al. 1994). Furthermore, based 
on the measurement approach adopted, HRQOL instruments can also be 
categorized into profile-based and preference-based instruments (Guyatt 1996). 
An instrument is profile-based if it measures different domains of HRQOL and 
generates a score for each of these domains, e.g. SF-36. If an instrument measures 
the utility of certain health outcomes, the instrument is preference-based, e.g., the 
EuroQol 5-dimension (EQ-5D) (Rabin and de Charro 2001) and Short Form 6-
dimension (SF-6D) (Brazier, Roberts et al. 2002), both of which provide a single 
overall health utility score enabling calculation of quality-adjusted life years 
(QALYs) for health economic analysis. 
 
HRQOL instruments are usually developed in one country or socio-cultural 
context. A standardised validation process is recommended (Guillemin, 
Bombardier et al. 1993) before an instrument can be applied in other countries 
and socio-contexts, in order to assess psychometric properties such as reliability, 
internal consistency, construct validity and sensitivity.  





2.3. HRQOL in ESRD patients  
Chronic dialysis has a great impact on patients’ HRQOL, including reduced 
physical functioning, reduced social interaction, increased risk of depression, and 
a variety of symptoms commonly noted in ESRD patients, such as muscle 
weakness, restless legs, and post-dialysis fatigue (Finkelstein, Story et al. 2009). 
HRQOL is an important predictor of clinical outcomes for ESRD patients. Several 
large studies have demonstrated that poor HRQOL could independently predict 
death and hospitalization of dialysis patients (Lowrie, Curtin et al. 2003, Mapes, 
Lopes et al. 2003) and therefore HRQOL has been suggested to be used as a 
valuable supplement to clinical outcome measures.  
 
Many instruments have been used to assess HRQOL for ESRD patients (Glover, 
Banks et al. 2011). The most commonly used generic HRQOL measures are the 
SF-36 and EQ-5D. The most frequently used disease-specific measure is the 
KDQOL instruments. The decision on which instruments to use depends on the 
research objectives. Using generic profile-based tools such as the SF-36 could 
enable the comparison with general population and other patient populations. 
Generic preference-based instruments such as the EQ-5D become more widely 
used when a study calls for the use of health utility measure to establish the cost 
effectiveness of treatments. However, generic HRQOL measures may not be 
sensitive to many of the health problems specific to those with ESRD and so their 
suitability in this population is limited. Disease-specific instruments are designed 
to capture the changes and differences within a specific population. The KDQOL-





36 appears to be most appropriate when a disease-specific instrument is required. 
It has been suggested that, whenever possible, both generic profile- and 
preference-based measures and disease-specific instruments are applied to ESRD 
patients (Manns, Johnson et al. 2002).  
 
HRQOL of patients undergoing ESRD treatment is affected by both medical and 
nonmedical factors. Literature has consistently revealed that the clinical variables, 
such as more co-morbidities, a lower albumin and haemoglobin level were 
independently related to poorer quality of life (Merkus, Jager et al. 1997, Mittal, 
Ahern et al. 2001, Plantinga, Fink et al. 2007). Demographic and social factors 
such as age, gender, living status, and income have been found to be associated 
with HRQOL in some studies (Kao, Lai et al. 2009, Seica, Segall et al. 2009, 
Bayoumi, Al Harbi et al. 2013).  
 
3. Cost-effectiveness analysis (CEA) 
3.1. Definition of CEA 
Economic evaluation is increasingly used to inform the decisions of various 
health care systems about which health care interventions to fund using limited 
resources. One generally used form of economic evaluation is the cost-
effectiveness analysis (CEA) using quality-adjusted life years (QALYs) as the 
effectiveness measure. It is also referred to as cost-utility analysis (CUA) 
(Drummond MF 1997). These findings would provide information about how to 
allocate finite resources between numerous competing interventions and 





programmes. On the basis that health care programmes and interventions aim to 
impact on individuals’ length of life and HRQOL, the QALY reflects these two 
aspects in a single measure and remains a major generic measure of health that 
has been used in a large range of clinical areas.  
 
As previously stated, two main approaches have been used to evaluate HRQOL in 
CEA studies, profiled-based and preference-based HRQOL measures. Validated 
generic or disease-specific profile-based HRQOL instruments can be used to 
provide comprehensive and multidimensional assessment of HRQOL in 
evaluating alternative health interventions (Revicki 1996). A preference-based 
HRQOL instrument measures the strength of a respondent’s preference for 
different health states. Utilities are quantified on a scale from 1 (anchored as 
perfect health or the best possible health state) to 0 (anchored as death or the 
worst possible health state), which can be combined with survival data to 
calculate QALYs. Therefore it is well accepted that preference-based HRQOL is 
an important and necessary component to define “effectiveness” and should be 
integrated into economic evaluations of healthcare interventions (Bootman JL 
1999).  
 
3.2. CEA about treatment of ESRD 
Some studies have compared the cost-effectiveness of HD and PD. Generally, PD 
was more cost-effective than HD (de Wit, Ramsteijn et al. 1998, Haller, Gutjahr 
et al. 2011). One UK study concluded that HD may be more cost-effective than 





CAPD (Kirby and Vale 2001) while the studies done in Malaysia and Chile 
showed that the cost-effectiveness of both modalities were nearly equal (Hooi, 
Lim et al. 2005, Pacheco, Saffie et al. 2007). Table 1.1 presents the cost-
effectiveness results of HD and PD from the literature.  
 
Table 1.1 Cost-effectiveness results of HD and PD 
Country Study period Results  
USA 2004-2006 PD>HD 
UK 1999 HD>PD 
Sweden 2000 PD>HD 
The Netherlands 1997 PD>HD 
Finland 1991-1996 PD>HD 
Greece Not clear PD>HD 
Australia 2001-2008 PD>HD 
Malaysia 1980-2001 Similar  
Thailand 1997-2003 PD>HD 
Chile 2005 Similar  
 
Due to the differences in survival and costs associated with each treatment, and 
health services provision and financing system between these countries and 
Singapore, existing evidence may not be used to formulate clinical practice 
guidelines or health policies in Singapore. The effectiveness and cost-
effectiveness of PD and HD in Singapore is not known; therefore, it is critical to 
investigate the cost effectiveness of managing dialysis patients in Singapore using 
local data.  





4. Research objectives 
This project will provide the first evidence for the potential of PD as an 
alternative of the conventional HD in Singapore. In the short term, this evidence 
will throw some light on the directions of future clinical and health services 
research in end-stage renal disease; in the long term, the evidence might 
contribute to the formulation of clinical practice guidelines or health policies and 
cost-effective management of end-stage renal disease in Singapore.  
The two major aims of the present project are as follows: 
 
First, the present project is to validate and assess suitable generic and disease-
specific HRQOL instruments for Singaporean patients with ESRD and on dialysis. 
The objectives of these studies are summarized as follows:  
1. To validate the disease-specific quality of life instrument Kidney Disease 
Quality of Life (KDQOL-36) for assessing dialysis patients in Singapore. 
2. To validate and compare the performance of two widely used preference-
based HRQOL instruments, EQ-5D and SF-6D, in dialysis patients. 
 
The second aim is to assess the effectiveness and cost-effectiveness of different 
dialysis modalities. The objectives of these studies are summarized as follows:  
3. To identify associated factors of the HRQOL of dialysis patients and 
compare the HRQOL between HD and PD patients. 
4. To compare the survival outcomes of HD and PD in Singapore. 





5. To estimate the costs of each dialysis modality and assess the cost-
effectiveness of HD, CAPD, APD in Singapore. 
 
5. Organization of the thesis 
The content of this thesis is arranged in such a way that each of the subsequent 




 chapter assesses the validity of the KDQOL-36 instruments. This chapter 




 chapter compares two preference-based HRQOL instruments, EQ-5D and 
SF-6D, in ESRD patients. This chapter has been published in The European 




 chapter reports the associated factors of HRQOL of ESRD patients. This 
chapter has been published in Quality of Life Research Year 2015, Volume 24, 




 chapter reports the survival outcomes of the HD and PD modalities in 
Singapore. This chapter has been published in PLOS ONE Year 2015, Volume 10, 
Issue 10, Page e0140195. 
  







 chapter assesses the cost-effectiveness of the HD and PD treatment 
options in Singapore. This chapter has been published in Nephrology (Carlton) 
Year 2015 (Epub ahead of print). 
 
The last chapter is a recapitulation of the major findings of the project. 
Contributions and limitations of this project and research questions to be 














Validation of the Kidney Disease Quality of Life Questionnaire  











End-stage renal disease (ESRD) is permanent loss of renal function requiring 
either chronic dialysis or renal transplantation. Worldwide, the incidence of 
ESRD is high and projected to increase due to the increasing prevalence of 
diabetes and hypertension. At the end of 2010, the number of ESRD patients 
receiving renal replacement therapy is estimated to reach 1.4 million (Moeller, 
Gioberge et al. 2002), with incidence growing by approximately 8% annually 
(Schieppati and Remuzzi 2005). In Singapore, the total number of patients on 
haemodialysis (HD) or peritoneal dialysis (PD) increased from 2461 at the end of 
1999 to 5521 at the end of 2013 (National Registry of Diseases Office 2014).  
 
Chronic dialysis has proven to be successful in prolonging life of ESRD patients 
and sustaining patients’ quality of life. But dialysis has substantial impact on 
patients’ physical and mental well-being, including reduced physical functioning, 
increased risk of depression and a variety of dialysis-related symptoms (Hays, 
Kallich et al. 1994, Walters, Hays et al. 2002). Hence, it is essential to assess and 
monitor the health-related quality of life (HRQOL) for ESRD patients undergoing 
dialysis.  
 
A variety of questionnaires have been used to assess HRQOL in ESRD patients 
including both generic and disease-specific questionnaires. Generic questionnaires 
have been designed to be widely applicable and enable comparisons to be made 
between different populations. However, when applied to a chronic disease 





population, generic instruments may be neither sufficiently sensitive nor 
approximately targeted to detect small changes which clinically might be 
important. Disease-specific instruments have been developed to assess aspects of 
HRQOL in relation to a disease of interest. They focus on concerns that are more 
relevant to a specific illness and treatment, and tend to be more effective in 
detecting treatment effects and are more responsive to changes in specific 
conditions. Although being potentially more sensitive to the characteristics of a 
specific population, disease-specific questionnaires are usually not applicable to 
other populations. So it is recommended that a combination of questionnaires or a 
questionnaire that encompasses both a generic and disease-specific component 
should be used.  
 
The Kidney Disease Quality of Life (KDQOL) instrument is a self-report measure 
developed for individuals who have kidney disease and are on dialysis. The 
original KDQOL instrument was developed in 1994 and it has 134 items. Despite 
the good reliability and validity of the KDQOL, some investigators were reluctant 
to use it because of its length. Therefore, only selected items were used to create 
the short form version, 79-item KDQOL Short Form (KDQOL-SF) ("The 
KDQOL Working Group") and an even shorter version KDQOL 36-Item 
(KDQOL-36) ("The KDQOL Working Group"). All the three KDQOL versions 
include both generic and disease-specific components for the assessment of 
HRQOL, providing summary scores for comparing with other populations and 
disease-specific scores for assessing the impact of dialysis. The KDQOL-SF, 





which contains the 36 questions from the Medical Outcomes Study 36-Item Short 
Form (SF-36) and 43 kidney-specific items, was widely used in clinical research 
(Carmichael, Popoola et al. 2000, Saban, Bryant et al. 2010, Braga, Peixoto et al. 
2011). The KDQOL-36, containing the Medical Outcomes Study 12-Item Short 
Form (SF-12) and 24 kidney-specific items, has also been increasingly used to 
measure the HRQOL of ESRD patients (Gorodetskaya, Zenios et al. 2005, 
Veerappan, Arvind et al. 2012). In the United States, it is mandated by the Center 
for Medicare Services that dialysis facilities to perform routine measurements of 
HRQOL preferentially using the KDQOL-36 questionnaire, with additional 
instruments if appropriate (Finkelstein, Wuerth et al. 2009). 
 
Although the English and Chinese versions of the KDQOL have been developed 
for years, the KDQOL instrument was introduced into Singapore only recently. 
Two previous studies have validated the English (Joshi, Mooppil et al. 2010) and 
Chinese (Cheung, Seow et al. 2012) versions of the KDQOL-SF for local ESRD 
patients. Those studies, however, did not investigate the performance of the 
KDQOL-36 which is potentially more useful in busy clinics and dialysis centres 
because of its brevity.  
 
Hence, the objective of the present study was to validate the KDQOL-36 by using 
data from the previous validation study of KDQOL-SF English version.  
 
 







ESRD patients receiving HD in one of the 22 National Kidney Foundation (NKF) 
dialysis centres in Singapore were recruited and interviewed by trained research 
nurses during their dialysis sessions. In a face-to-face interview, the 79-item 
KDQOL-SF questionnaire was administered together with questions assessing 
patients’ demographic and health characteristics. Participation in this study was 
voluntary and data was collected from December 2006 through January 2007. 
Inclusion criteria were: (1) a diagnosis of ESRD; (2) at least 21 years old; and (3) 
on HD for more than 3 months. This study was approved by the Institutional 




The KDQOL-SF contains 79 items, including the first 36 items from the SF-36 
(version 1.0) and the 43 kidney disease-specific items. The SF-36 is the most 
widely used health survey throughout the world because it is brief and 
comprehensive, readily available, psychometrically-sound, and of proven 
usefulness in measuring health status and monitoring health outcomes in both 
general and patient populations. The SF-36 measures perceived health using 8 
subscales (i.e. physical functioning, role physical, bodily pain, general health, 
vitality, social functioning, role emotional and mental health) and generate 2 
summary scales: the physical component summary (PCS-36) and mental 





component summary (MCS-36).  The kidney disease-specific items measure the 
disease-related and dialysis-related health problems in a total of 11 dimensions 
(Hays Ron D 1997): symptoms/problems (12 items), effects of kidney disease on 
daily life (8 items), burden of kidney disease (4 items), work status (2 items), 
cognitive function (3 items), quality of social interaction (3 items), sexual 
function (2 items), sleep (4 items), social support (2 items), dialysis staff 
encouragement (2 items), and patient satisfaction (1 item). 
 
KDQOL-36 
The KDQOL-36 is constructed using a subset of the original KDQOL-SF items, 
the first 12 items from the SF-12 (version 1.0) and the 24 disease-specific items. 
All the SF-12 items are from the SF-36 health survey. Like the SF-36, it could 
generate two generic health measures: the physical component summary (PCS-12) 
and mental component summary (MCS-12). PCS-12 and MCS-12 are designed as 
equivalents of PCS-36 and MCS-36 using fewer items (Ware JE 1998). Both 
versions of the two summary measures use the same metric on which the score of 
50 corresponds to the average functioning level of the general population (Ware 
JE 1998), with higher scores indicating better functioning or well-being. The 24 
kidney disease-specific items could measure 3 dimensions (symptoms/problems 
[12 items], effects of kidney disease on daily life [8 items], and burden of kidney 
disease [4 items]). 
 





For both versions of KDQOL, all kidney disease items are measured on a 5-point 
Likert scale. The scale scores are aggregated item scores transformed to the range 
of 0-100, with higher scores indicating better quality of life. Higher PCS or MCS 
scores reflect better perceived health. 
 
Data analysis 
Internal consistency reliability and item-to-scale correlation were assessed using 
Cronbach’s α and Pearson’s r, respectively. An α value ≥ 0.70 (Nunnally JC 1994) 
and r value ≥ 0.40 (Ware and Gandek 1998) was considered satisfactory. 
  
Scaling assumptions were examined using factor analysis, which is one of the 
most important and powerful methods for establishing construct validity of 
psychometric tests for an instrument. It attempts to provide a formal method of 
exploring correlation structure and provides a method for investigating the 
internal structure of an instrument. Factor analysis can model a number of factors 
simultaneously, using the inter-item correlations and standard deviations (SDs) to 
estimate the models and carry out statistical ‘goodness-of-fit’ tests. Confirmatory 
factor analysis (CFA) was performed first and when CFA showed poor model fit, 
exploratory factor analysis (EFA) was performed. The SF-12 and kidney disease 
items were analyzed separately. In the CFA for SF-12, we tested the two-factor 
model structure on which the recommended SF-12 scoring method is based (Ware, 
Kosinski et al. 1996). Specified item loading in the model were the physical 
functioning, role physical and bodily pain items on one factor (i.e. PCS), the 





mental health, role emotion and social functioning items on the other factor (i.e. 
MCS), and the vitality and general health items on both factors (Ware JE 1995, 
Ware, Kosinski et al. 1996).  
 
The CFA for kidney disease items used a three-factor structure, following the 
recommended KDQOL scoring methods (Hays Ron D 1997). Model fit was 
assessed using the comparative fit index (CFI) and the root mean square error of 
approximation (RMSEA). CFI value >0.90 (B.Kline 2005) and RMSEA value 
≤0.10 (Chen, Curran et al. 2008) would suggest a good fit. EFA was performed 
using principal component analysis with oblique rotation. Kaiser strategy 
(dropping all components with eigenvalues < 1.0) and scree plot were used to 
determine the number of factors ("UCLA Academice Technology Services/Stat 
Computing"). A factor loading value of 0.5 would indicate that an item is clearly 
related to a factor (Ware JE 1998). 
 
Construct validity, which refers to the degree to which a test measures what it 
claims, or purports, to measure, was assessed by examining the correlation 
between kidney disease scales and generic scales. We hypothesized that the 
correlation would be weak to moderate (Patrick and Deyo 1989, Ren, Kazis et al. 
1998, Ren, Kazis et al. 2005).  
 
Criterion validity, the agreement between a scale and a known gold standard 
measure of the same concept, was tested by examining the correlation between 





PCS-12 and PCS-36 and between MCS-12 and MCS-36. We hypothesized that 
the correlation between the SF-12 and SF-36 summary scales would be high. 
 
Factor analysis was performed using Mplus (version 6.11) (Linda K. Muthen 
1998-2007). Other statistical tests were performed with SPSS (version 19). A 
correlation coefficient value of >0.5, 0.35 to 0.50, <0.35 was considered as strong, 
moderate, and weak correlation, respectively (Guyatt, Berman et al. 1987, Juniper 




A total of 394 patients who were interviewed in English were included in this 
study. The mean (standard deviation) age was 52.4 (11.7) years and the mean 
(standard deviation) duration of dialysis was 69.0 (50.6) months. Other 














Table 2.1. Demographic characteristics of the study sample (N=394) 
  No. Percent% 
Gender     
 Male  220 55.8 
 Female  174 44.2 
Race     
 Chinese  196 49.7 
 Malay  138 35.0 
 Indian 57 14.5 
 Others  3 0.8 
Marital status    
 Married  262 66.5 
 Divorced/Single/Widowed 132 33.5 
Education status   
 No schooling  21 5.3 
 Primary/Secondary 308 78.2 
 JC and above 48 12.2 
Employment status 
 Full-time employed 85 21.6 
 Part-time employed/not employed 293 74.4 
 
 
Kidney disease scales 
The Cronbach’s α for kidney disease scales were 0.906 (symptoms/problems), 
0.881 (effects of kidney disease or dialysis), and 0.822 (burden of kidney disease). 
Item-to-scale correlation ranged from 0.896 to 0.903 for symptoms/problems, 
0.861 to 0.883 for effects of kidney disease or dialysis, and 0.763 to 0.791 for 
burden of kidney disease, and all items of kidney disease scales were correlated 
with their own scales more strongly than with other scales (Table 2.2).  
 
The results of CFA for kidney disease items are shown in Figure 2.1. A three-
factor model reflecting the grouping of the items to form 3 kidney scales fit the 
data well (CFI=0.934, RMSEA=0.085). Pearson’s r values between the kidney 





scales and the generic scales were weak to moderate (range: 0.286-0.418) (Table 
2.3). 
 
Table 2.2. Item-to-scale correlation coefficients of the kidney disease scales 
   Symptom/problems Effects Burden 
Symptoms/problems    
Soreness in muscles 0.898 0.385 0.167 
Chest pain 0.899 0.370 0.132 
Cramps 0.897 0.308 0.199 
Itchy skin 0.898 0.366 0.177 
Dry skin 0.902 0.373 0.185 
Shortness of breath 0.897 0.476 0.216 
Faintness or dizziness 0.896 0.363 0.197 
Lack of appetite 0.900 0.413 0.137 
Washed out or drained 0.897 0.395 0.128 
Numbness in hands or feet 0.898 0.347 0.199 
Nausea or upset stomach 0.896 0.314 0.123 
Problems with access site 0.903 0.300 0.166 
Effects of kidney disease on daily life   
Fluid restriction 0.422 0.864 0.219 
Dietary restriction 0.441 0.861 0.258 
Ability to work around the house 0.411 0.863 0.293 
Ability to travel  0.394 0.870 0.181 
Being dependent on doctors and other medical staff 0.437 0.861 0.258 
Stress or worries 0.439 0.865 0.450 
Sex life 0.264 0.882 0.344 
Personal appearance 0.379 0.863 0.226 
Burden of kidney disease    
KD interferes too much with life 0.214 0.297 0.784 
Too much time spent on KD 0.167 0.301 0.764 
Frustrated  0.221 0.304 0.763 
Burden on family 0.209 0.282 0.791 
*Correlation with own hypothesized scale was higher than with others 
 
 





Figure 2.1. A three-factor model for the disease-targeted scales obtained 












Table 2.3. Pearson’ r values between the disease scales and the generic scales 
Scale  PCS-12 MCS-12 
Symptoms and problems 0.414 0.343 
Effects of KD 0.333 0.341 




The Cronbach’s α for PCS and MCS were 0.737 and 0.704, respectively. The 
CFA results of SF-12 showed that the 2-factor model that forms the basis of the 
PCS and MCS had poor overall fit to the observed data (CFI=0.956, 
RMSEA=0.167). In EFA, a three-factor structure achieved good model fit 
(CFI=0.999, RMSEA=0.027). Item loadings after oblique rotation are displayed 
in Table 2.4. Based on item content, the factors were role functioning, physical 
health, and mental health. Correlation was 0.750 between PCS-12 and PCS-36 

















































 Factor 1 Factor 2 Factor 3 
General health    
Health rating in general 0.431 0.356 0.507* 
Physical functioning    
Limitations in moderate physical activities 0.539* 0.779* 0.337 
Limitations in climbing several flights of stairs 0.436 0.840* 0.321 
Role physical     
Accomplished less due to physical health 0.969* 0.453 0.262 
Limited in kind of work or activities due to physical health 0.945* 0.467 0.247 
Bodily pain     
Pain interference with work inside or outside home 0.633* 0.397 0.563* 
Role emotional     
Accomplished less due to emotional problems 0.972* 0.275 0.438 
Not careful in work or activities due to emotional problems 0.919* 0.201 0.404 
Mental health     
Feel calm and peaceful 0.287 0.246 0.822* 
Feel down hearted and blue 0.461 0.238 0.573* 
Vitality     
Having a lot of energy 0.385 0.412 0.646* 
Social functioning    
Interference of physical health or emotional problems with social 
activities 
0.418 0.259 0.532* 
Eigenvalues  5.662 1.794 1.208 
*Values equal or greater than 0.5 were considered satisfactory    






Overall, our study suggests that KDQOL-36 has good validity and reliability 
among Asian haemodialysis patients in Singapore.  
 
The kidney disease scales showed desirable reliability and validity. First, the three 
kidney disease scales yielded satisfactory internal consistency reliability 
(Cronbach’s α>0.7), similar to results in a previous study (Cheung, Seow et al. 
2012). Second, consistent with previous studies (Hays Ron D 1997, Saban, Bryant 
et al. 2010), both item-to-scale correlation and factor analysis supported the 
scaling assumptions for the kidney disease scales. In addition, the weak to 
moderate correlation between the kidney disease scales and the generic PCS and 
MCS suggested that those two types of scales measure related but different 
domains of quality of life, confirming construct validity.  
 
The generic SF-12 exhibited similarly good internal consistency reliability as a 
previous study (Montazeri, Vahdaninia et al. 2009) and satisfactory validity when 
using the SF-36 summary component measures as the criterion, which is also 
consistent with previous studies (Wee, Davis et al. 2008, Failde, Medina et al. 
2010).  
 
Nevertheless, factor structure of SF-12 items differed from the ‘physical-mental’ 
structure that is supported by data from Western populations (Ware, Kosinski et al. 
1996, Kontodimopoulos, Pappa et al. 2007). On the other hand, the three factors 





(i.e., physical health, mental health, and role functioning) emerging from our data 
correspond to 3 factors of the SF-36 observed in a Japanese population 
(Suzukamo, Fukuhara et al. 2011). In that study, a three-factor model (physical, 
mental, and role-social) fit the data better than the two-factor structure (physical 
and mental). In addition, the SF-36 scales repeatedly presented a two-factor 
structure that is different from the recommended measurement model in almost all 
Asian populations (Fukuhara, Ware et al. 1998, Fuh, Wang et al. 2000, Thumboo, 
Fong et al. 2001, Yu, Coons et al. 2003). These findings suggest that the SF-12 
items may be better used to construct three rather than two general health scales. 
Actually, Dr. John Ware called for research into a 3-compoment model (physical, 
mental, and role and social) as a substitution of the current 2-component models 
for measuring health status (Ware 2003).  
 
Our study has two limitations. The data used in our study was from KDQOL-SF 
rather than KDQOL-36. The administration of the items not belonging to the 
KDQOL-36 during the interviews might have contributed to the results we 
observed in this study. Also, the study did not include the clinical data and 
patients undergoing peritoneal dialysis. If the clinical data was available, the 
know-groups validity could be assessed by testing the hypothesis that a scale 
should show difference, in the expected direction, between groups of subjects 
known to differ in certain clinical characteristics. Given these limitations, our 
findings should be treated as preliminary. Further research is necessary to test 





KDQOL-36 when it is administered alone and by examining its correlation with 
clinical outcomes in Singapore. 
 
CONCLUSION 
In conclusion, both kidney disease and generic scales of the KDQOL-36 appear 
valid and reliable for measuring health-related quality of life of haemodialysis 
patients in Singapore. It may be better to construct an additional general health 



















Comparison of the Preference-based EQ-5D and SF-6D  

















In financially constrained health systems across the world, economic evaluation is 
increasing used to inform the decisions on whether or not to adopt new but 
expensive therapeutic options. One generally used form of economic evaluation is 
the cost-utility analysis (CUA) (Drummond MF 1997) by quantifying the health 
outcomes using quality-adjusted life years (QALYs). To generate quality-of-life 
weights for calculating QALYs in such analysis, preference-based health-related 
quality of life (HRQOL) measures are commonly used.  
 
The EuroQol 5-dimension (EQ-5D) (Dolan 1997) and the Short Form 6-
dimension (SF-6D) (Brazier, Roberts et al. 2002) are widely used preference-
based HRQOL instruments for economic evaluations of clinical interventions and 
health programs. Both instruments describe a respondent’s health status using a 
multi-attribute health-state classification system and then produce a utility value 
from a scale anchored by 0 (death) and 1 (full health) for the respondent. Both 
instruments measure health in terms of physical function, pain, and mental health, 
and have a scoring function derived from statistical modelling of preference for 
multi-deficit health states elicited from the UK general population. However, 
some differences between these two instruments need to be noted. These two 
instruments differ in the number of health states defined by the descriptive system 
(SF-6D: 18,000; EQ-5D: 243) and the methods used to measure health 
preferences (SF-6D: standard gamble; EQ-5D: time trade-off). The EQ-5D score 
is usually generated from the EQ-5D self-report questionnaire while the SF-6D 





score is usually obtained from the items of profiled-based Medical Outcomes 
Study-Short Form instruments. When used in empirical studies, the EQ-5D and 
SF-6D also exhibited important differences. First, the health utility measured by 
the EQ-5D was generally lower than that measured by the SF-6D (Conner-Spady 
and Suarez-Almazor 2003, Brazier, Roberts et al. 2004, Xie, Li et al. 2007). 
Second, the two instruments showed differential sensitivity to difference in health 
status. The EQ-5D was more efficient in detecting group differences than SF-6D 
in a Spanish general population sample (Cunillera, Tresserras et al. 2010); on the 
other hand, the SF-6D showed greater discriminatory power than EQ-5D in two 
general population samples (Petrou and Hockley 2005, Luo, Wang et al. 2012), 
hearing-impaired adults (Barton, Bankart et al. 2004), and liver transplant patients 
(Longworth and Bryan 2003).  
 
ESRD, requiring chronic dialysis, has become an increasing public health 
problem and reported to have negative impact on HRQOL of patients. The EQ-5D 
and SF-6D have been widely used in these patients (Manns, Johnson et al. 2002, 
Gerard, Nicholson et al. 2004, Lee, Morgan et al. 2005, Rajan, Lai et al. 2013) 
and one study assessing the validity of the two measures in haemodialysis patients 
found that they performed similarly except for the higher response rate of EQ-5D 
(Gerard, Nicholson et al. 2004). However, the sensitivity of these two instruments 
and the impact of different index scores on QALYs estimates in patients with 
ESRD were not formally assessed; hence, which one of the two instruments is 
more suitable for use in this population is unknown. Additionally, in clinical 





practice, due to the limitation of data, the preference-based data could only be 
mapped from the profile measures if the health utility scores are of interest. The 
SF-12 based EQ-5D scores have been shown to perform similarly as the directly 
monitored EQ-5D. But it is not clear whether the derived EQ-5D could quantify 
the similar known-group differences for ESRD patients as the actual EQ-5D. 
 
The objective of the present study was to assess the psychometric properties of 
the EQ-5D and SF-6D instruments in patients with ESRD in terms of agreement, 
construct validity, and sensitivity. The differences in health utility scores for 
patients in better and worse health status were also compared between EQ-5D 





A consecutive sample of patients with ESRD was recruited from the nephrology 
clinics at National University Hospital, a tertiary referral hospital in Singapore, 
from June 2012 to May 2013. Inclusion criteria were: 1) a diagnosis of ESRD; 2) 
on haemodialysis (HD) or peritoneal dialysis (PD) for at least 3 months; 3) ability 
to communicate in English or Chinese; and 4) well enough to be interviewed. 
After providing written consent, each patient was interviewed by a trained 
interviewer using a standardized questionnaire (available in identical English or 
Chinese version) including the 5-level EQ-5D (EQ-5D-5L) self-report 





questionnaire, the Kidney Disease Quality of Life 36-Item (KDQOL-36), and 
questions assessing socio-demographic characteristics. Clinical data such as co-
morbidities (measured as Charlson Comorbidity Index [CCI]), blood haemoglobin 
level, and dialysis adequacy (measured as Kt/V [K: dialyzer clearance of urea, t: 
dialysis time, V: volume of distribution of urea]) was obtained from patients’ case 
notes. CCI is an age-modified score of number and severity of co-morbidities 
proven to prognosticate for mortality in ESRD (Di Iorio, Cillo et al. 2004), with 
higher scores indicating the presence of multiple and/or advanced stage(s) of 
various medical condition(s).  
 
Instruments and measures 
EQ-5D-5L 
The EQ-5D-5L self-report questionnaire has 5 items (mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression) (Rabin and de Charro 2001), 
with 5 descriptive levels for each item. The 5 levels in the EQ-5D-5L include “no 
problem”, “slight problems”, “moderate problems”, and “severe problems” for all 
five items, and “unable to do” for mobility, self-care and usual activities or 
“extreme problems” for pain/discomfort and anxiety/depression. Respondents 
choose one level for each item to describe their health status on the day of 
interview. Responses to the five EQ-5D items define a health state for which an 
index score can be generated to indicate its value to the general public. The index 
score is anchored by 0 (death) and 1 (full health), with higher scores 
corresponding to higher utility. The range of the score is from -0.594 to 1.00. 





Both the English and Chinese versions of the EQ-5D-5L have been validated in 
Singapore (Lee CF 2012, Wong KY 2012). In this study, the EQ-5D-5L index 
scores were calculated using a mapping (“crosswalk”) function (van Hout, 
Janssen et al. 2012) to reflect the values of the described health states to the 
general UK population (Dolan 1997).  
 
KDQOL-36 
The KDQOL-36 (Kalantar-Zadeh and Unruh 2005) is a commonly used kidney 
disease-specific HRQOL instrument. It comprises the Medical Outcomes Study 
12-Item Short Form (SF-12) and 3 scales targeting kidney disease and dialysis:  
symptoms/problems (12 items), effects of kidney disease on daily life (8 items), 
and burden of kidney disease (4 items). Scores of the 3 kidney scales range from 0 
to 100, with higher scores indicating better perceived health. The English version 
of the KDQOL-36 has been validated in Singaporean HD patients(Yang, Wang et 
al. 2013). The KDQOL-36 was scored using the recommended algorithm 
(available from: www.gim.med.ucla.edu/kdqol). 
 
SF-6D 
The SF-6D is a multi-attribute health classification system consisting of 6 
domains: physical functioning, role limitation, social functioning, pain, mental 
health, and vitality, with 2-6 levels for each domain. Responses to 7 of the SF-12 
items can be mapped to health states defined by the SF-6D classification system 
and the utility-based SF-6D index score can be generated (Brazier and Roberts 





2004). The SF-6D index score derived from the SF-12 reflects the health 
preferences of the UK general population, ranging from 0.29 (the worse possible 
health state) to 1.00 (full health) (Brazier and Roberts 2004). The SF-6D index 
scores based on data from English- and Chinese-speaking respondents in 
Singapore have demonstrated to be equivalent (Wee, Cheung et al. 2004).  
 
SF-12 based EQ-5D index 
Responses to the SF-12 can also be used to estimate the EQ-5D index score using 
a mapping function. Such estimates are mainly for QALYs calculation in cost-
utility analyses and burden-of-disease studies when the EQ-5D data is not 
available. Among the available mapping functions (Franks, Lubetkin et al. 2004, 
Lawrence and Fleishman 2004, Sullivan and Ghushchyan 2006), the one 
developed by Franks et al (Franks, Lubetkin et al. 2004) was reported to be most 
accurate in estimating the group means (Chuang and Kind 2009) and was used in 
this study. This mapping function was based on the physical and mental 
component summary scores of the SF-12. The derived EQ-5D index score ranges 
from -0.113 to 0.980 (Franks, Lubetkin et al. 2004).  
 
Statistical analysis 
Continuous variables were presented as means and standard deviations, while 
categorical variables were shown as frequencies and proportions. For EQ-5D-5L 
and SF-6D index scores, we reported the distributions of scores and the mean (SD) 
and median, minimum, maximum, and the percentage of respondents with the 





minimum/maximum scores. Agreement between the EQ-5D-5L and SF-6D scores 
was examined by calculating the intraclass correlation coefficient (ICC) and using 
a Bland-Altman plot. An ICC≥0.7 suggests an acceptable level of agreement 
(Peter M. Fayers 2007). 
 
Convergent construct validity was investigated by examining the correlation 
between the EQ-5D-5L and the SF-6D utility scores using Pearson’s correlation 
coefficient (r). We expected the two different utility scores to show a strong 
correlation (r≥0.5) (Conner-Spady and Suarez-Almazor 2003, Longworth and 
Bryan 2003, Gerard, Nicholson et al. 2004), in support of the construct validity. 
Known-groups validity was accessed by testing a priori hypothesis that the utility 
scores would be higher in patients in better health status (Manns, Johnson et al. 
2002, Petrou and Hockley 2005, Molsted, Prescott et al. 2007) than those in worse 
health. The study sample was dichotomized into subgroups in better and worse 
health status according to their co-morbidities (indicated by CCI), haemoglobin 
level, dialysis adequacy (indicated by Kt/V), and KDQOL-36 kidney disease-
targeted scale scores. We used mean as the cut-off value for all the variables 
except for Kt/V. The cut-off values for Kt/V were defined separately for HD and 
PD patients. The sensitivity to detect differences in known groups was assessed 
using the ‘‘relative efficiency (RE)’’ statistic and effect size (Cohen’s d). The RE 
statistic is defined as the ratio of F statistics in the analysis of variance (ANOVA) 
tests of the differences in scores between patients who have ‘‘better’’ health and 





those who have “worse” health (Peter M. Fayers 2007). For each pair of known 
groups, we used the F statistic of the EQ-5D-5L index as the reference 
(RE=1) to calculate the RE value of the SF-6D index. As higher F-statistic values 
correspond to higher statistical significance, the instrument with a higher RE 
value would be considered as more efficient or discriminative than its comparator. 
The effect size was calculated using the difference in mean scores divided by the 
pooled SD (Cohen 1988). We used the threshold values of 0.2, 0.5, and 0.8 to 
define small, moderate, or large effect size, respectively (Cohen 1988). 
Differences in the mean scores of the EQ-5D-5L, SF-6D and SF-12-based EQ-5D 
(derived EQ-5D) between the known groups differing in health status were also 
compared.  
 
All statistical analyses were performed using STATA (release 11.2; Stata Corp, 




Characteristics of patients and the HRQOL scores 
A total of 150 patients with ESRD and on dialysis participated in this study, 
including 75 on HD and 75 on PD. Demographic and clinical characteristics are 
shown in Table 3.1. Patients’ mean age was 60.1 years; nearly half of them had a 
CCI >5 (47.3%). The mean duration of dialysis, either HD or PD, was 5.65 years. 
The range of the dialysis adequacy (i.e. Kt/V) in HD and PD patients was 0.68-





2.30/dialysis and 0.38-4.58/week, respectively, and the mean haemoglobin level 
was 11.2 g/dL.  
 
Distributions of the EQ-5D-5L and SF-6D are displayed in Table 3.2. The EQ-
5D-5L score ranged from -0.59 to 1, with 27.3% of subjects reported perfect 
health. In contrast, the SF-6D score ranged from 0.37 to 1, with 2.7% of 
respondents scoring the highest value. The EQ-5D-5L was skewed towards 
perfect health, whereas the distribution of SF-6D was normal (Figure 3.1).  
 
Although the mean scores for the EQ-5D-5L (0.68) and the SF-6D (0.70) were 
similar, the ICC between the EQ-5D-5L and the SF-6D utility scores was 0.36. 
The Bland-Altman plot demonstrated wide limits of agreement interval (i.e., 1.21) 
and the EQ-5D-5L scores were systemically lower than the SF-6D in subjects 















Table 3.1. Patients’ Characteristics 
Characteristics  Total, n=150 
Age (year), mean (SD) 60.1 (11.6) 
Gender, n (%)  
    Female  73 (48.7) 
    Male  77(51.3) 
Marital status, n (%)  
    Single  20 (13.3) 
    Married  110 (73.3) 
    Widowed/divorced/separated 20 (13.4) 
Ethnicity, n (%)  
    Chinese  106(70.7) 
    Malay  33(22.0)  
    Indian  8(5.3)  
    Others  3(2.0) 
Educational level, n (%)  
    No formal and primary 69(46.0)  
    Secondary and post-secondary 57(38.0)  
    Tertiary and above 24(16.0) 
Working status, n (%)  
    Working 27(18.0)  
    Not working 54(36.0)  
    Retired 69(46.0) 
Living status, n (%)  
    Alone  14 (9.3) 
    With family members 133 (88.7) 
    In nursing home 3(2.0) 
Length on dialysis (year), mean (SD) 5.65 (5.58) 
Co-morbidity, n (%)  
    CCI≤5 79(52.7)  
    CCI>5 71(47.3) 
Haemoglobin level (g/dL), mean(SD)  11.2 (1.8) 
Kt/V, mean (SD)   
    Haemodialysis (HD) 1.43 (0.26) 
    Peritoneal dialysis (PD) 2.35 (0.75) 
CCI: Charlson Comorbidity Index   










Table 3.2. Descriptive statistics of EQ-5D-5L and SF-6D utility scores   
Scale  N. Mean (SD) Median Min  % patients on 
“floor” 
(worst health score) 
Max  % patients at 
“ceiling” 
(best health score) 
EQ-5D-5L  150 0.68 (0.36) 0.81 -0.59 0.7 1 27.3 
SF-6D 150 0.70 (0.14) 0.70 0.37 0.7 1 2.7 





Figure 3.1. Distribution of EQ-5D-5L and SF-6D utility scores 






Figure 3.2. Bland-Altman plot of difference in utility scores between the SF-




Pearson’s correlation coefficient between the EQ-5D-5L and the SF-6D was 0.53 
(p<0.01), indicating a strong correlation. As expected, patients with less co-
morbidity (CCI≤5), higher haemoglobin level (>11g/dL), or higher Kt/V 
(HD:>1.45/dialysis; PD:>2.35/week) had higher mean EQ-5D-5L and SF-6D 
scores than patients with more co-morbidity, lower haemoglobin level, or lower 
dialysis adequacy although statistical significance was not achieved in some of 
the comparisons (Table 3.3). Both the EQ-5D-5L and SF-6D indices 
differentiated between subjects with different KDQOL-36 kidney disease-specific 





scale scores; the mean EQ-5D-5L and SF-6D scores were higher for the patients 
with higher scale scores, which was in line with expectations (Table 3.3).    
 
Sensitivity 
Using the EQ-5D-5L index as the reference, the relative efficiency (RE) values of 
the SF-6D were more than 1 for comparison of known groups defined by 
haemoglobin level and the three KDQOL-36 kidney disease-specific scales, while 
the RE values were less than 1 in the known group comparisons of patients with 
differing CCI and Kt/V levels (Table 3.3). The effect sizes showed the same trend 
in the relative sensitivity of the two instruments (Table 3.3). 
 
The EQ-5D-5L (range: 0.03 to 0.23) showed greater differences between the 
known groups than did the SF-6D (range: 0.002 to 0.12) (Table 3.3). The 
magnitude of difference between known groups measured by the derived EQ-5D 
score (range: 0.01 to 0.22) was also greater than that defined by the SF-6D. For 
example, the differences in the mean scores of the EQ-5D-5L, SF-6D and derived 
EQ-5D between respondents with less dialysis-related symptoms and those with 











Table 3.3. Known-groups construct validity and sensitivity of EQ-5D and  
SF-6D 
Grouping variable N. 
Mean (SD) 
EQ-5D-5L SF-6D Derived EQ-5D 
Comorbidity      
   CCI>5  71 0.58(0.41) 0.69(0.14) 0.62(0.21) 
   CCI≤5  79 0.78(0.29) *** 0.71(0.14) 0.67(0.20) 
   Mean difference  0.20 0.02 0.05 
   RE  1 0.07 - 
   Effect size  0.554 0.145 - 
Haemoglobin (g/dL)    
   ≤11  74 0.63(0.37) 0.67(0.12) 0.60(0.21) 
   >11  69 0.73(0.36) 0.73(0.15)** 0.69(0.18)** 
   Mean difference  0.10 0.06 0.09 
   RE  1 2.50 - 
   Effect size  0.277 0.437 - 
Dialysis adequancy (Kt/V)    
   Low 72 0.63(0.39) 0.691(0.14) 0.63(0.20) 
   High 45 0.72(0.30) 0.693(0.13) 0.64(0.19) 
   Mean difference  0.09 0.002 0.01 
   RE  1 0.005 - 
   Effect size  0.262 0.017 - 
Disease-targeted scales of KDQOL-36 ‡ 
Symptoms       
   ≤80  55 0.55(0.39) 0.63(0.14) 0.51(0.21) 
   >80  94 0.78(0.30)*** 0.75(0.12)*** 0.73(0.15)*** 
   Mean difference  0.23 0.12 0.22 
   RE  1 2.02 - 
   Effect size  0.675 0.959 - 
Effects      
   ≤76  65 0.59(0.40) 0.64(0.13) 0.55(0.21) 
   >76  85 0.76(0.31)** 0.74(0.13)*** 0.72(0.17)*** 
   Mean difference  0.17 0.10 0.17 
   RE  1 2.45 - 
   Effect size  0.487 0.763 - 
Burden      
   ≤43   79 0.67(0.36) 0.66(0.12) 0.59(0.21) 
   >43  71 0.70(0.36) 0.75(0.14)*** 0.71(0.18)*** 
   Mean difference  0.03 0.09 0.12 
   RE  1 36.88 - 
   Effect size  0.107 0.651 - 
*P<0.05, **P<0.01, ***P<0.001 (t-tests of the difference between known groups).  
‡Cut-off values are median scores.  
SD: standard deviation, CCI: Charlson Comorbidity Index, RE: relative efficiency 






In this study, we found that the preference-based EQ-5D-5L and SF-6D health 
indices were both valid in Asian patients with ESRD but the two utility measures 
were sensitive to different outcomes, were not interchangeable, and may lead to 
different cost-effectiveness results if they are used to quantify health benefits in 
economic evaluations of interventions for patients with ESRD. These findings 
highlighted the importance of investigating the performance of different 
preference-based HRQOL instruments in outcomes research of ESRD.  
 
Correlation between the EQ-5D-5L and the SF-6D was strong, similar to that 
found in one previous study of HD patients (Gerard, Nicholson et al. 2004) and 
other patient groups (Hawthorne, Richardson et al. 2001, Conner-Spady and 
Suarez-Almazor 2003, Longworth and Bryan 2003). Moreover, both measures 
demonstrated known-groups validity as the mean utility scores differed in the 
expected directions between subgroups of patients in better and worse health 
status. However, similar to previous studies (Petrou and Hockley 2005, van Stel 
and Buskens 2006, Xie, Li et al. 2007), agreement between the EQ-5D-5L and 
SF-6D scores was poor, suggesting that the two index scores have important 
difference and therefore that they cannot be used interchangeably.  
 
Overall, both instruments were able to discriminate between different patient 
groups. The SF-6D was superior to the EQ-5D-5L in differentiating patients with 
different levels of self-reported health outcomes measured using the KDQOL-36 





scales while the EQ-5D-5L was more sensitive to clinical outcomes, such as 
comorbid conditions and Kt/V. The greater sensitivity of the SF-6D compared to 
EQ-5D-5L to kidney disease related HRQOL could be due to two reasons. First, 
the recall period of the SF-12 items that SF-6D was based on (“last 4 weeks”) and 
the KDQOL items is identical, while the EQ-5D-5L items assess the health 
problems on the day of the survey (“today”). Second, the SF-12 was administered 
as a component of the KDQOL instrument in the study, which means the 
responses to the SF-12 and kidney disease items would have been subject to 
context effect (Obradovic, Lal et al. 2013) and therefore exhibited inflated 
association. Context effects suggest that the answer to a survey question can be 
affected by prior items that respondents have answered.  Hence, the better 
sensitivity of SF-6D observed in this study should be interpreted with caution. 
The greater sensitivity of EQ-5D-5L than the SF-6D to clinical outcomes was 
consistent with the finding from a cross-sectional study of the general Spanish 
population (Cunillera, Tresserras et al. 2010). However, findings from studies of 
England and US general populations (Petrou and Hockley 2005, Luo, Wang et al. 
2012) and hearing-impaired adults and liver transplant patients (Longworth and 
Bryan 2003, Barton, Bankart et al. 2004) showed that the SF-6D derived from the 
SF-36 was more discriminative than EQ-5D. These seemingly contradicting 
findings could be explained by the inferior discriminative power of the SF-12-
derived SF-6D as compared to SF-36-derived SF-6D (Luo, Wang et al. 2012). It 
is possible that the EQ-5D-5L was more discriminative than the SF-6D in patient 
populations comprising very ill patients. This is because the EQ-5D has a much 





wider score range (-0.59 to 1.0) than the SF-6D (0.29 to 1.0) and therefore is more 
able to capture the distinction between better and worse health status (Obradovic, 
Lal et al. 2013).    
 
The greater differences between ESRD patients in differing health shown by the 
EQ-5D as compared to the SF-6D in our study was consistent with results from 
previous cross-sectional studies of other patient groups (Xie, Li et al. 2007, 
Sorensen, Linde et al. 2012, Obradovic, Lal et al. 2013). Moreover, the EQ-5D 
also exhibited greater utility gains than the SF-6D in longitudinal studies (van Stel 
and Buskens 2006, Barton, Sach et al. 2009, Adams, Walsh et al. 2010). These 
results suggested that the use of the EQ-5D instrument, as opposed to the SF-6D 
instrument, in cost-utility analysis may lead to more favorable estimates of 
(incremental) effects and an incremental cost-effectiveness ratio (ICER) and 
therefore greater chance of adopting more expensive but also more effective 
treatment alternatives (McDonough and Tosteson 2007, Sach, Barton et al. 2009). 
Therefore, choice between the two preference-based HRQOL instruments for 
economic evaluations should be carefully justified, as it may have an important 
impact on the results and the decision making based on such results.  
 
One possible reason for this difference is that the full range of EQ-5D-5L scores 
(i.e. 1.59) is more than two times greater than that of the SF-6D (i.e. 0.71). A 
previous study found that utility measures using a narrower scale range were more 
likely to result in smaller magnitude of differences in health utility (Stavem, 





Froland et al. 2005). In our study, the greater difference in utility scores between 
the known groups according to the EQ-5D-5L as compared to SF-6D was mainly 
because the EQ-5D-5L scores were much lower than the SF-6D scores for the 
worse groups, suggesting that the SF-6D might have overestimated very poor 
health status due to its relatively high lower limit of scale. Indeed, previous 
studies found that the SF-6D produced higher utility estimates than the EQ-5D in 
patients with inflammatory arthritis (Barton, Sach et al. 2009, Harrison, Davies et 
al. 2009). Therefore, the EQ-5D-5L might be more suitable than the SF-6D for 
studying patients in very poor health status.  
 
The derived EQ-5D score exhibited greater magnitude of differences between 
known groups than the SF-6D and would lead to favorable ICERs as the EQ-5D-
5L. Even though it has been reported that the derived EQ-5D index 
underestimated the health utility in the range of the actual EQ-5D scores from 0.5 
to 0.8 (Franks, Lubetkin et al. 2004), which was also observed in our study, the 
SF-12-based EQ-5D index could be used to estimate QALYs in cost-utility 
analysis when the investigators prefer to use EQ-5D index score but the relevant 
health outcome is only measured by the SF-12 or SF-36. 
 
Our results need to be interpreted in light of several study limitations. First, the 
EQ-5D-5L was scored using a “crosswalk” method in which the EQ-5D-5L health 
states are mapped to the EQ-5D-3L values (EuroQolGroup). EQ-5D-5L utility 
values directly elicited from the general population, which may be available soon, 





might exhibit different results. Second, the mapping function we used to derive 
EQ-5D scores from the SF-12 was developed using data from a general 
population sample, although the derived EQ-5D performed very similarly as the 
EQ-5D-5L in quantifying differences between groups of patients in differing 
health status. Last, the sensitivity of the two instruments to change in health status 
during dialysis has not been assessed since this study was cross-sectional.   
 
CONCLUSION  
In conclusion, both the EQ-5D-5L and the SF-6D are valid and sensitive health 
utility measures for assessing ESRD patients. However, it appears that the EQ-5D 
(both actual and derived) would lead to more favorable cost-effectiveness results 

















Health-Related Quality of Life of Asian Patients  
with End-stage Renal Disease (ESRD) in Singapore 






Worldwide, haemodialysis (HD) and peritoneal dialysis (PD) are established renal 
replacement therapies for ESRD patients. However, chronic dialysis has a great 
impact on patients’ health-related quality of life (HRQOL), including reduced 
physical functioning, reduced social interaction, increased risk of depression, and 
a variety of symptoms commonly noted in ESRD patients, such as muscle 
weakness, restless legs, and post-dialysis fatigue (Finkelstein, Wuerth et al. 2009). 
Previous studies have reported that both incident and prevalent dialysis patients 
have much poorer HRQOL compared to the general population (Merkus, Jager et 
al. 1997, Walters, Hays et al. 2002). In addition, HRQOL is an important 
predictor of clinical outcomes for ESRD patients. Several large studies have 
demonstrated that poor HRQOL could independently predict death and 
hospitalization of dialysis patients (Lowrie, Curtin et al. 2003, Mapes, Lopes et al. 
2003) and therefore HRQOL has been suggested to be used as a valuable 
supplement to clinical outcome measures (Lowrie, Curtin et al. 2003).  
 
Many instruments have been used to assess HRQOL for ESRD patients (Hays, 
Kallich et al. 1994, Glover, Banks et al. 2011), including generic and disease-
specific instruments. Generic HRQOL measures can be profile-based (such as the 
Medical Outcomes Study 36-Item Short Form Health Survey [SF-36]) that are 
intended to provide information on the general functioning and well-being of 
individuals, or preference-based (such as the EuroQol 5-dimension [EQ-5D]), 
which provides a single overall health utility score enabling calculation of quality-





adjusted life years (QALYs) for health economic analysis (Rabin and de Charro 
2001). Disease-specific HRQOL measures (such as the Kidney Disease Quality of 
Life Short Form [KDQOL-SF]) take into account particular concerns of patients 
as a direct result of their kidney disease or dialysis treatment (Hays, Kallich et al. 
1994). It has been suggested that, whenever possible, both generic profile- and 
preference-based measures and disease-specific instruments are applied to ESRD 
patients (Manns, Johnson et al. 2002).  
 
HRQOL of patients undergoing ESRD treatment is affected by both medical and 
nonmedical factors. Literature has consistently revealed that the clinical variables, 
such as more co-morbidities, a lower albumin and haemoglobin level were 
independently related to poorer quality of life (Merkus, Jager et al. 1997, Mittal, 
Ahern et al. 2001, Plantinga, Fink et al. 2007). Demographic and social factors 
such as age, gender, living status, and income have been found to be associated 
with HRQOL in some studies (Kao, Lai et al. 2009, Seica, Segall et al. 2009, 
Bayoumi, Al Harbi et al. 2013). Knowledge about the risk factors of poor 
HRQOL can guide the identification of more vulnerable ESRD patients and the 
development of interventions to help them.  
 
However, there are still knowledge gaps that need to be addressed. First, only 
factors of the HRQOL of HD patients were extensively investigated (Walters, 
Hays et al. 2002, Seica, Segall et al. 2009, Mandoorah, Shaheen et al. 2014). 
Whether those are also factors affecting the HRQOL of PD patients is not known. 





Second, how the nonmedical factors impact on HRQOL measured using 
preference-based instruments has not been fully understood. Only a couple of 
studies have investigated factors associated with the EQ-5D score (Manns, 
Johnson et al. 2003, Sakthong and Kasemsup 2012). Third, there are very few 
studies of the factors affecting HRQOL of Asian ESRD patients. Findings about 
the HRQOL of ESRD patients in western countries may not be generalized to 
Asian patients, who have fewer co-morbidities and a markedly lower death rate 
than Caucasians (Robinson, Joffe et al. 2006).  
 
The present study aimed to identify socio-demographic and clinical factors 
associated with HRQOL of multiethnic Asian patients with ESRD and on dialysis. 
The effect of dialysis modality was also examined. 
 
METHODS 
Patients and data 
Data used in this study was from two cross-sectional surveys, conducted between 
2009 (Griva, Kang et al. 2014) and 2013 (Yang, Lau et al. 2014). In the first 
survey, participants were recruited from the PD centre of Singapore General 
Hospital (SGH) and National Kidney Foundation (NKF) HD centres between 
2009 and 2011. Patients were approached by research assistants either while 
awaiting consultation with a nephrologist at the PD centre or while receiving HD. 
A battery of questionnaires was either taken home, self-completed, and 
subsequently mailed back or administered by an interviewer in a home visit. The 





survey questionnaires included the KDQOL-SF and questions assessing socio-
demographic characteristics. In the second survey, PD patients were recruited 
from the renal centre of the National University Hospital (NUH) and HD patients 
were recruited from the nephrology clinics and the HD centre of the same hospital, 
from June 2012 to July 2013.  All patients were interviewed by a trained 
interviewer in the clinic or dialysis centre where they were recruited. 
Questionnaires administered by the interviewer included the Kidney Disease 
Quality of Life 36-Item (KDQOL-36) and questions assessing socio-demographic 
characteristics. 
 
Clinical data including co-morbidity used to generate the Charlson Comorbidity 
Index (CCI), serum albumin and haemoglobin, dialysis vintage (i.e. time on 
dialysis), and dialysis adequacy (i.e. Kt/V) were retrieved from medical records 
for participants of both surveys. A lower CCI indicates that a patient has fewer 
co-morbidities. Participants of the two surveys who met the following criteria 
were included in the present study: (1) a diagnosis of ESRD, (2) HD/PD for at 




The 79-item Kidney Disease Quality of Life Short Form (KDQOL-SF) and its 
short form, the 36-item KDQOL (KDQOL-36) are two commonly used 
instruments developed specifically for individuals who have kidney disease and 





are on dialysis (Hays, Kallich et al. 1994). Both instruments generate generic and 
disease-specific HRQOL scales (Hays, Kallich et al. 1994) which have been 
validated in ESRD population in Singapore (Cheung, Seow et al. 2012, Yang, 
Wang et al. 2013).  
 
The KDQOL-SF includes the SF-36 items and 43 items generating 11 kidney 
disease-specific scales (symptoms/problems [12 items], effects of kidney disease 
on daily life [8 items], burden of kidney disease [4 items], work status [2 items], 
cognitive function [3 items], quality of social interaction [3 items], sexual 
function [2 items], sleep [4 items], social support [2 items], dialysis staff 
encouragement [2 items], patient satisfaction [1 item]). 
 
The KDQOL-36 contains a subset of the KDQOL-SF items, including the SF-12 
items and 24 items to obtain 3 kidney disease-specific scales (symptoms/problems 
[12 items], effects of kidney disease on daily life [8 items], and burden of kidney 
disease [4 items]). The three disease-specific subscales can be summated into the 
kidney disease component summary (KDCS) score which ranges from 0 to 100, 
with higher scores reflecting better perceived health 
(http://www.rand.org/health/surveys_tools/kdqol/faq.html).  
 
The SF-12 is a generic instrument which is developed using a subset of the SF-36 
items. It can generate two summary scores, physical component summary (PCS) 





and mental component summary (MCS), with higher scores representing better 
physical and mental health, respectively. 
 
Two utility-based measures, Short Form 6-dimension (SF-6D) and EQ-5D, can be 
obtained from the SF-12 using established mapping functions. Anchored by 0 
(death) and 1 (full health), both measures indicate the value of a respondent’s 
health status as perceived by the general public. Responses to 7 of the SF-12 
items can be mapped to health states defined by the SF-6D classification system 
and the SF-6D score can be generated using a standardized algorithm (Brazier and 
Roberts 2004), while the SF-12 PCS and MCS scores of a respondent can be used 
to calculate the EQ-5D index score (Franks, Lubetkin et al. 2004). The EQ-5D 
index score is best to be generated from responses to the EQ-5D self-report 
questionnaire which is a health-state classification system consisting of five 
dimensions (mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression) and three descriptive levels for each dimension (no problems, 
moderate problems, and extreme problems) (Rabin and de Charro 2001). 
Nevertheless, mapping has been considered as an accepted approach to obtaining 
utility values when only data on profile-based measures is available for cost-
effectiveness analyses (Franks, Lubetkin et al. 2004, Sullivan and Ghushchyan 
2006). Both EQ-5D and SF-6D measures have been demonstrated to be valid and 
sensitive in Singaporean dialysis patients (Yang, Lau et al. 2014).   
  
 





Statistical analysis  
The KDQOL-SF items from the first survey were used to construct the KDQOL-
36 and then we combined this data with the KDQOL-36 data collected in the 
second survey. The PCS, MCS, and KDCS scores were generated from the 
KDQOL-36 using recommended methods (www.gim.med.ucla.edu/kdqol). The 
SF-6D score was calculated based the scoring algorithm developed by Brazier et 
al (Brazier and Roberts 2004) and the EQ-5D score was generated using the 
mapping function developed by Franks et al (Franks, Lubetkin et al. 2004). 
 
Characteristics of the pooled study samples were described using means and 
standard deviation (SD) for continuous variables and frequencies and percentages 
for categorical variables. In the analysis that examined the factors of HRQOL, all 
factor variables were coded into categorical variables in case the association was 
not linear. Continuous variables were coded using either recommended clinically 
meaningful values (Chen, Hung et al. 2000, Korevaar, Merkus et al. 2002, Lopes, 
Bragg-Gresham et al. 2007, Molsted, Prescott et al. 2007, Plantinga, Fink et al. 
2007, Hopper and Cole 2008, Lacson, Xu et al. 2009), or means/medians when 
the former was absent. Existing and derived categorical variables in which there 
was any category with <30 observations were re-coded by collapsing those 
categories with other categories to increase statistical power. The factor variables 
included in this analysis were age (young [<45 years]/middle-aged [45-60 
years]/old [>60 years]), gender (male/female), ethnicity (Chinese/Malay/Indian or 
other), educational level (low [no formal/primary/secondary]/high 





[tertiary/above]), marital status (married/other [single/widowed/separated/ 
divorced]), housing type (private residence/public residence), co-morbidity (low 
CCI [<5]/high CCI [≥5]), albumin level (low [<37g/l]/high [≥37g/l]), 
haemoglobin level (low [<11g/dl]/high [≥11g/dl]), modality (HD/PD), dialysis 
vintage (short [<3.5 years]/long [≥3.5 years]) and dialysis adequacy (low/high).  
 
Univariate two-sample t-tests or analysis of variance tests were initially used to 
examine the association of each factor with each of the five HRQOL scores (PCS, 
MCS, KDCS, SF-6D, and EQ-5D). In the subsequent multivariate linear 
regression analysis, all socio-demographic and clinical variables were entered into 
five models, one for each of the HRQOL score, regardless of their statistical 
significance in the univariate analysis.   
 
All analyses were performed using STATA (release 11.2; Stata Corp, College 
Station, TX, USA) statistical software. Statistical significance was set at p<0.05. 
 
RESULTS  
After excluding cases with missing data, 502 dialysis patients were included in 
this study. The patients’ mean (SD) age was 57.1 (11.9) years, with 52.4% male, 
66.5% Chinese, 73.1% having secondary or lower education, 69.1% married, and 
90.6% living in the public residence. Mean (SD) CCI of the patients was 4.74 
(1.61), and the mean (SD) serum albumin and haemoglobin levels were 33.3 (14.3) 
g/l and 11.20 (1.6) g/dl, respectively. With regard to dialysis parameters, 47% of 





the patients were undergoing HD while 53% on PD, the mean (SD) duration on 
dialysis therapy was 4.88 (4.70) years, and the mean (SD) Kt/V values were 1.49 
(0.29) per dialysis for HD and 2.33 (0.88) per week for PD. There were 
significant differences in age, gender, ethnicity, educational level, co-morbidity, 
albumin level, haemoglobin level and dialysis vintage between patients 
undergoing HD and those undergoing PD. Full socio-demographic and clinical 
characteristics are shown in Table 4.1. 
 
Mean (SD) PCS, MCS and KDCS scores for the patients were 37.9 (9.7), 46.4 
(10.8) and 57.6 (18.1), respectively. Mean (SD) health utility score was 0.66 (0.12) 
based on SF-6D and 0.60 (0.21) based on EQ-5D.  
 
In the univariate analysis, the following statistically significant associations with 
HRQOL scores were found (Table 4.2):  young age (<45 years), high educational 
level (tertiary or above), low CCI (<5), high albumin level (≥37g/l), high 
haemoglobin level (≥11g/dl), and HD modality with higher PCS; old age (>60 
years) with higher KDCS; high educational level, private residence, and high 
albumin level with higher SF-6D; young age, high educational level, high 
albumin level and high haemoglobin level with higher EQ-5D scores. No 


















Socio-demographic      
  Age (year), mean (SD) 57.1 (11.9) 54.5 (10.6) 59.3 (12.5) <0.001 
  Gender, n (%)     <0.01 
    Male  263 (52.4) 142 (60.2) 121 (45.5)  
    Female  239(47.6) 94 (39.8) 145 (54.5)  
  Ethnicity, n (%)     <0.01 
    Chinese  335 (66.5) 137 (58.1) 198 (74.4)  
    Malay  123 (24.5) 76 (32.2) 47 (17.7)  
    Indian or other 44 (8.8) 23 (9.7) 21 (7.9)  
  Educational level, n (%)    <0.001 
    Low (no/primary/secondary) 367 (73.1) 152(64.4) 215 (80.8)  
    High (tertiary/above) 135 (26.9) 84 (35.6) 51 (19.2)  
  Marital status, n (%)    0.32 
    Married  347 (69.1) 158 (66.9) 189 (71.1)  
    Other (single/widowed/separated/divorced) 155 (30.9) 78 (33.1) 77 (28.9)  
  Housing type, n (%)     0.06 
    Private residence  47 (9.4) 16(6.8) 31 (11.7)  
    Public residence 455 (90.6) 220 (93.2) 235 (88.3)  
Clinical      
  Charlson Comorbidity Index, mean (SD)  4.74 (1.61) 4.36 (1.45) 5.08 (1.67) <0.001 
  Albumin (g/l), mean (SD) 33.3 (14.3) 36.7 (19.5) 30.3 (5.6) <0.001 
  Haemoglobin (g/dl), mean (SD) 11.2 (1.6) 11.5 (1.43) 10.9 (1.69) <0.001 
Dialysis      
  Dialysis vintage (year) , mean (SD) 4.88 (4.70) 6.37  (5.54) 3.55 (3.28) <0.001 
  Dialysis adequacy      
















Table 4.2. Mean HRQOL scores by patients’ characteristics 
Characteristic n PCS MCS KDCS  SF-6D EQ-5D 
Age         
  Young (<45 years) 66 41.45 46.04 57.43  0.679 0.662 
  Middle-aged (45-60 years) 218 37.29 45.85 55.41  0.649 0.586 
  Old (>60 years) 218 37.50 47.17 59.82  0.658 0.606 
Gender         
  Male  263 38.66 46.33 56.83  0.663 0.616 
  Female  239 37.12 46.58 58.42  0.651 0.592 
Ethnicity         
  Chinese  335 38.34 46.41 57.41  0.662 0.611 
  Malay  123 37.43 46.98 59.09  0.647 0.604 
  Indian or other 44 36.12 45.23 54.67  0.645 0.559 
Educational level        
  Low (no/primary/secondary) 367 37.17 46.16 57.50  0.649 0.589 
  High (tertiary/above) 135 39.99 47.22 57.83  0.678 0.646 
Marital status        
  Married  347 38.11 46.35 56.96  0.657 0.607 
  Other (single/widowed/separated/divorced) 155 37.51 46.69 59.00  0.656 0.599 
Housing type         
  Private residence  47 39.09 47.64 61.19  0.696 0.633 
  Public residence 455 37.81 46.33 57.22  0.653 0.601 
Co-morbidity        
  Low CCI (<5) 224 39.21 46.34 56.66  0.665 0.624 
  High CCI (≥5) 278 36.89 46.53 58.34  0.651 0.588 
Albumin (g/l)        
  Low (<37) 395 36.95 46.16 57.05  0.646 0.586 
  High (≥37) 107 41.54 47.52 59.58  0.698 0.672 
Haemoglobin (g/dl)        
  Low (<11) 223 36.71 46.22 57.61  0.652 0.582 
  High (≥11) 279 38.90 46.63 57.57  0.661 0.622 
Modality         
  HD (haemodialysis) 236 38.88 46.31 56.32  0.660 0.619 
  PD (peritoneal dialysis) 266 37.08 46.57 58.72  0.654 0.591 
Dialysis vintage (Year)        
  Short (<3.5) 255 37.80 45.55 56.85  0.650 0.590 
  Long (≥3.5) 247 38.06 47.38 58.35  0.664 0.619 
Dialysis adequacy (Kt/Va)        
  Low 101 37.77 47.18 57.11  0.668 0.614 
  High  401 37.94 46.26 57.71  0.654 0.602 
CCI Charlson comorbidity index, PCS physical component summary, MCS mental component 
summary, KDCS kidney disease component summary 
SF-6D Short Form 6-dimension, EQ-5D EuroQol 5-dimension 
Significant between-group differences are in bold 
aLow Kt/V was defined as\1.2/dialysis and\2.0/week for HD and PD, respectively       
 





In the multivariate analysis, the following factors were significantly associated 
with higher HRQOL scores (Table 4.3): young or old age, low CCI, high albumin 
level, and high haemoglobin level with PCS; long dialysis vintage (≥3.5 years) 
with MCS; and old age, Malay ethnicity, and PD modality with KDCS. As for the 
health utility scores, low CCI, high albumin level and high haemoglobin level 
were associated with higher EQ-5D, and high albumin level was positively 





































Table 4.3. Regression coefficients in multiple linear regression analysis of 
HRQOL scores 
Independent variable (reference group) 
Dependent variable 
PCS MCS KDCS  SF-6D EQ-5D 
Age group (young [<45 years])       
  Middle-aged [45-60 years] -3.45* 1.08 0.285  -0.017 -0.052 
  Old [>60 years] -1.02 4.06 7.30*  0.014 0.024 
Gender (male)       
  Female -0.43 0.50 1.09  -0.002 -0.002 
Ethnicity (Chinese)       
  Malay -1.11 1.55 4.05*  -0.007 -0.0004 
  Indian or other -2.22 -1.38 -2.80  -0.019 -0.054 
Educational level (low [no/primary/secondary])       
  High [tertiary/above] 1.10 1.39 1.08   0.016 0.032 
Marital status (other [single/widowed/separated/divorced])    
  Married  1.73 -0.77 -3.05  0.008 0.021 
Housing type (public residence)       
  Private residence 0.62 1.00 3.54  0.031 0.018 
Co-morbidity (low CCI [<5])       
  High CCI [≥5] -3.03* -1.69 -2.94  -0.028 -0.069* 
Albumin level (low [<37g/l])       
  High [≥37g/l] 4.03*** 1.43 3.61  0.050** 0.076*** 
Haemoglobin (low [<11g/dl])       
  High [≥11g/dl] 1.92* 0.60 0.60  0.009 0.038* 
Modality (HD [haemodialysis])       
  PD [peritoneal dialysis] -0.28 0.97 3.88*  0.008 0.002 
Dialysis vintage (short [<3.5years])       
  Long [≥3.5years] -0.35 2.12* 2.59  0.013 0.023 
Dialysis adequacy (low Kt/Va)         
  High Kt/V -0.05 -1.22 1.07  -0.014 -0.021 
CCI Charlson comorbidity index, PCS physical component summary, MCS mental component 
summary, KDCS kidney disease component summary 
SF-6D Short Form 6-dimension, EQ-5D EuroQol 5-dimension  
* p<0.05, ** p<0.01, *** p<0.001. 
aLow Kt/V was defined as <1.2/dialysis and <2.0/week for HD and PD, respectively      
 
 






In the present study, we identified the socio-demographic and clinical factors 
which could impact on the HRQOL of a multiethnic patient population in Asia. 
We found that age, ethnicity, co-morbidity, albumin level, haemoglobin level, 
dialysis modality and dialysis vintage were associated with HRQOL.   
 
Age and ethnicity are the only two socio-demographic characteristics associated 
with quality of life in dialysis patients. Old patients reported better quality of life 
than young patients in all aspects except for physical heath; in contrast, middle-
aged patients had similar or worse quality of life than the young. This non-linear 
relationship between age and quality of life was also observed in two previous 
studies (DeOreo 1997, Rebollo and Ortega 2002). That older patients had better 
quality of life than younger patients may be due to the greater adaptation to 
chronic disease and lower expectation of older patients compared with younger 
patients. We found that Malays were less impacted by the kidney disease and 
dialysis as measured by the KDCS scale than Chinese. This might be because 
Malays get more support from their families and their religious belief. Better 
family functioning of Malays than Chinese has been reported in a previous study 
of the Singaporean general population (Leow, Griva et al. 2013). Nevertheless, 
without an adequate assessment of family functioning and religious experience of 
the ESRD patients, we could not be sure whether this is the real reason. Putting 
these together, the results suggested that young and middle-aged Chinese dialysis 





patients in Singapore might be at higher risk of poorer HRQOL and therefore may 
deserve more attention. 
 
Among the significant clinical variables, co-morbidity, albumin level and 
haemoglobin level were associated with physical health and health utility. Similar 
associations were observed in previous studies (Merkus, Jager et al. 1997, Lopes, 
Bragg-Gresham et al. 2007, Sakthong and Kasemsup 2012). For example, a study 
of more than 9,000 HD patients from seven countries concluded that co-morbidity, 
hypoalbuminemia and low haemoglobin level were independently and 
significantly associated with poorer physical health (Lopes, Bragg-Gresham et al. 
2007). A study of PD patients using EQ-5D instrument showed that significant 
predictors of high health utility included low co-morbidity, high albumin level 
and use of erythropoietin (Sakthong and Kasemsup 2012). These associations 
make good sense from the clinical perspective. Comorbidity reveals the 
significant concurrent diseases in addition to ESRD and it is known to affect 
survival and hospitalization (Khan 1998, Beddhu, Bruns et al. 2000) and thus 
would be expected to impact HRQOL. A low albumin is an indicator of 
malnutrition and has been found to be strongly related to higher risk for mortality 
and morbidity in dialysis patients(Valderrabano, Jofre et al. 2001, Lopes, Bragg-
Gresham et al. 2007), while a low haemoglobin level indicates anemia which is 
one consequence of chronic kidney disease and should be corrected using 
erythtopoietin (Lopes, Bragg-Gresham et al. 2007, Sakthong and Kasemsup 2012). 
Thus, it is plausible to expect an association between low albumin or 





haemoglobin level and poorer HRQOL. Hence, these results suggest that 
healthcare professionals should pay more attention to patients with poorer co-
morbidity profiles and actively treat patients with malnutrition or anemia.  
 
Two dialysis characteristics were also found to be associated with certain aspects 
of quality of life. First, patients with longer dialysis vintage reported similar or 
better mental health than patients with shorter dialysis vintage. It should be noted 
that dialysis vintage is the only significant predictor of mental health in the study. 
This result is different from those of previous studies that found either reverse or 
no association between dialysis vintage and quality of life (Hsieh, Lee et al. 2007, 
Sayin, Mutluay et al. 2007, Anees, Hameed et al. 2011). One of the possible 
explanations for these different results is that the effect of dialysis vintage on 
quality of life might be not linear. Since most of our patients had a quite long 
dialysis duration, it may be possible that patients who have been dialyzed for a 
longer time have developed ways to process, integrate and adjust to psychological 
demands of illness while those in the early stages of dialysis have not been able to 
adapt to the demands of dialysis as successfully. Such processes of cognitive 
adaptation have been documented in many other patient groups (Taylor 1983) and 
have been shown to improve mental health (Taylor and Brown 1988). 
Nevertheless, these assumptions need to be tested with an appropriate 
measurement of patients’ perception of illness, which is beyond the scope of the 
present study and therefore could be a topic of future studies. Second, PD patients 
perceived less impact of kidney disease and dialysis treatment than HD patients. 





This result is consistent with several studies in which the KDQOL was used to 
compare the quality of life between HD and PD patients. In those studies, PD 
patients reported more encouragement from the staff, more patient satisfaction, 
less effects and less burden compared to the HD patients (Manns, Johnson et al. 
2003, Molsted, Prescott et al. 2007, Griva, Kang et al. 2014). Other than that, the 
HRQOL of PD and HD patients was similar according to generic measures, which 
is in line with previous studies (Mau, Chiu et al. 2008, Thong, van Dijk et al. 
2009, Griva, Kang et al. 2014). Although HD patients exhibited better physical 
health than PD patients, the difference substantially attenuated after adjusting for 
socio-demographic and clinical characteristics. This was not surprising because 
PD patients were older and more likely to be females than HD patients. Older age 
and female gender were associated with lower physical functioning in Singapore 
(Thumboo, Chan et al. 2002, Leow, Griva et al. 2013) as well as many other 
populations (Mittal, Ahern et al. 2001, Chiang, Peng et al. 2004, Mandoorah, 
Shaheen et al. 2014). The very small difference in the health utility of HD and PD 
patients as measured by SF-6D and EQ-5D indices suggests that the relative cost-
effectiveness of the two dialysis modalities in Singapore would be mainly 
determined by their survival outcomes and associated costs.    
 
The limitations of our study deserve consideration. First, the HRQOL data used in 
the present study was from two different versions of the KDQOL. The items 
included in the KDQOL-SF but not in the KDQOL-36 might have an impact on 
patients’ responses due to context effect or order effect (Peter M. Fayers 2007). 





Second, the EQ-5D used in this study was mapped from the SF-12 using a scoring 
algorithm. Although mapping is widely used to generate health utility scores from 
profile-based HRQOL measures, it is the second best alternative to the direct use 
of a preference-based measure (Rowen, Brazier et al. 2011). Third, this study was 
cross-sectional and the results could only show the association of various factors 
and HRQOL, making it difficult to make causal inference.  
 
CONCLUSION  
In conclusion, clinical characteristics are better predictors of the health-related 
quality of life in dialysis patients than socio-demographics in Singapore. More 
attention should be paid to patients with co-morbidity, malnutrition or anemia, as 
well as younger Chinese to improve the quality of life of this patient population. 
Lastly, there is no difference in health utility of patients who are treated with 



















Survival Outcomes of Haemodialysis and Peritoneal Dialysis in  
Patients with End-stage Renal Disease (ESRD) in Singapore  
 
 





End-stage renal disease (ESRD) has become a significant and growing public 
health problem worldwide. The global average prevalence of ESRD patients on 
dialysis was 215 per million population (Letsios 2011), and the total number of 
dialysis patients in 2010 was estimated to be close to two million (Grassmann, 
Gioberge et al. 2005). Asians have been reported to have higher prevalence rate of 
ESRD than Caucasians (Hall, Hsu et al. 2005).  In Singapore, the prevalence of 
ESRD was 1436.1 per million population in 2013 and the number of prevalent 
dialysis patients increased at an average rate of 8% per year from 1999 to 2013 
(National Registry of Diseases Office 2014). The dialysis population is projected 
to increase sharply due to the nation’s aging population and the high prevalence 
of diabetes (Tan, Chan et al. 2005).  
 
Haemodialysis (HD) and peritoneal dialysis (PD) are the two common forms of 
dialysis therapy for ESRD. The mortality of ESRD patients who are treated with 
the two modalities has been investigated in numerous observational studies (Heaf, 
Lokkegaard et al. 2002, Termorshuizen, Korevaar et al. 2003, Jaar, Coresh et al. 
2005, Huang, Cheng et al. 2008, McDonald, Marshall et al. 2009, Chang, Hsu et 
al. 2012, Yeates, Zhu et al. 2012, Kim, Kim et al. 2014). But which dialysis 
modality performs better in prolonging life of ESRD patients is not clear. Some 
studies showed the superior outcomes of HD (Termorshuizen, Korevaar et al. 
2003, Jaar, Coresh et al. 2005, McDonald, Marshall et al. 2009), whereas others 
demonstrated that PD was equivalent to HD (Huang, Cheng et al. 2008, Chang, 




Hsu et al. 2012), or even better for certain subgroups (Heaf, Lokkegaard et al. 
2002, Yeates, Zhu et al. 2012, Kim, Kim et al. 2014). Moreover, the vast majority 
of these comparisons were done in Western countries; in Asia, similar 
comparative studies were performed in Taiwan and Korea (Huang, Cheng et al. 
2008, Chang, Hsu et al. 2012, Kim, Kim et al. 2014). There was no such study 
from South-East Asia, home to more than 593 million people. 
 
Therefore, in this study, we aimed to compare the survival outcomes of patients 
starting different dialysis modalities using a multiethnic ESRD patient cohort 




The hospital registry contains data of newly diagnosed ESRD patients in National 
University Hospital (NUH), Singapore from January 2005 to December 2010. 
Patients were followed up for a maximum of 5 years (median 3.2 years). Adult 
patients (≥21-year-old) who began either HD or PD and survived the first 90 days 
of dialysis were included in this study. The dialysis modality on the 90
th
 day after 
the first service was considered as the initial modality. Patients were being 
censored for change of therapy or end of the study period, i.e. August 31, 2013. A 
total of 871 patients were included, of whom 641 initiated dialysis with HD and 
230 with PD. For each patient, the baseline demographic characteristics (age, 
gender and ethnicity), co-morbid conditions at dialysis initiation (presence of 




diabetes mellitus [DM], hypertension, cardiovascular disease [CVD], and 
hyperlipidemia) and laboratory tests, such as left ventricular ejection fraction 
(LVEF), haemoglobin, serum albumin, phosphate, parathyroid hormone (PTH), 
alkaline phosphatase (ALP), calcium, urate, urea and estimated glomerular 
filtration rate (eGFR) were recorded. The postal codes of patients’ home 
addresses were retrieved from NUH to determine housing type (public residence 
vs. private residence), as a surrogate measure of socioeconomic status (SES). The 
information about death (died/alive, date of death and cause of death) was 
obtained from the National Registry of Disease Office under the approval of 
Ministry of Home Affairs (MHA), Singapore. Patients’ NRICs were used to 
match with the databases of MHA to retrieve the all-cause death information.  
 
The Domain Specific Review Board, National Healthcare Group approved this 
study and waived the informed consent.  
 
Statistical analysis 
Categorical variables were presented as frequency and percentage for the two 
groups (HD and PD) separately and compared using either chi-square test or 
Fisher’s exact test as appropriate. Continuous variables were presented as means 
± standard deviation (SD) and compared using t-test. A two-sided p-value of less 
than 0.05 was considered statistically significant. Age was dichotomized into two 
groups (young [≤65-year-old]/old [>65-year-old]) in the analysis. In order to keep 




consistency within the whole thesis, a cut-off age of 60-year-old was also used as 
additional analysis.  
 
Survival analysis was performed using the flexible Royston-Parmar (RP) 
parametric model. The RP model is highly flexible alternative to the traditional 
Cox proportional hazards survival model when the assumption for the Cox model 
is violated (Royston and Parmar 2002). In initial analysis, the Cox assumption 
was violated. Royston-Parmar model is able to parametrically model baseline 
survival functions and it has been shown to greatly improve the ability to 
accurately predict survival of some patient populations than the Cox model, so 
some researchers recommended using RP model in prognosticating patient 
survival (Miladinovic, Kumar et al. 2012, Rooney, Byrne et al. 2013). Univariate 
and multivariate RP survival analysis was performed using step-wise backward 
selection procedure with p<0.05 as the significance threshold.  
 
The RP models were also estimated using a subsample of propensity score (PS) 
matched patients. Patients treated with PD were different from patients treated 
with HD in terms of age, comorbid conditions and some laboratory tests, which 
are important covariates associated with survival. Thus, we established study 
cohorts that were matched with propensity score. The propensity score was the 
estimated probability of being treated initially with PD and was calculated using 
the multivariate logistic regression model. The matching technique was the 
nearest-neighbor matching within calipers without replacement with 1-to-1 




matching (1 PD: 1 HD) and the caliper width was 0.2 of the SD of the logit of the 
propensity score (Austin 2011). This matching approach has been shown to result 
in the least biased treatment effect estimation among different PS-adjusted 
methods (Austin, Grootendorst et al. 2007). After matching, a subsample of 225 
patient pairs was formed and then, we tested the balancing of propensity scores 
for each variable between HD and PD groups. The estimated mean bias in 
propensity score was 4.9% and 15.1% in the propensity score matched sample and 
in the raw sample (before matching), respectively. There was no significant 
difference in demographic and clinical characteristics between patients initially 
treated with PD and those treated with HD in the matched sample. 
 
The same RP model was further applied to subgroups defined by age and diabetes 
mellitus (young without DM, old without DM, young with DM, and old with DM) 
and by age and cardiovascular disease (young without CVD, old without CVD, 
young with CVD, and old with CVD). 
 
The treatment effect on outcome was quantified using the hazard ratio (HR) 
estimate for PD patients, compared with HD patients, and its associated 95% 
confidence interval (CI). The values of HR >1 indicate a higher risk for death of 
PD than HD.  
 
All analyses were performed using STATA (release 11.2; Stata Corp, College 
Station, TX, USA) statistical software.  





Demographic and clinical characteristics are presented in Table 5.1. Patients 
initiating dialysis with PD (mean age: 64.3 years) were, on average, 6 years older 
than those initiating dialysis with HD (mean age: 58.2 years, p<0.001). There was 
higher proportion of females (57.4% versus 44.2%, p<0.01) and ethnic Chinese 
(66.1% versus 53.7%, p<0.01) in patients starting PD than those starting HD. At 
dialysis initiation, DM, hypertension, CVD and hyperlipidemia were more 
common among the PD patients.  In terms of lab tests, patients who started 
dialysis with PD had higher hemoglobin levels, higher albumin concentrations, 
lower phosphate levels, and higher eGFR than those who started dialysis with HD.  
 
During the 5-year follow-up period, there were 225 deaths among the patients 
initiating HD (mortality rate: 7.02%) and 157 deaths among patients initiating PD 
(mortality rate: 13.7%). Figure 5.1a shows that the mortality rates for patients 
starting dialysis with the two modalities were similar in the first 6 months (p=0.79, 
log-rank test) but started to differ after 6 months, with the mortality among those 
treated with PD initially being increasing at a higher rate. 
 
In multivariate flexible Royston-Parmar models, the risk of death was higher in 
patients starting PD than those starting HD (adjusted HR: 2.08; 95% CI: 1.67-2.59; 
p<0.001). Other significant predictors of higher risk of death were old age at 
diagnosis (>65-year-old) and presence of co-morbidity such as DM and CVD at 
the time of dialysis initiation (Table 5.2). Similar results were also observed using 




60-year-old as the cut-off age (adjusted HR: 2.10; 95% CI: 1.68-2.62; p<0.001). 
Figure 5.2 shows that the adjusted HR of death of patients initiating PD compared 
to patients initiating HD was significantly higher than 1 during the follow-up 
period except for the first 12 months of treatment (HR: 1.37; 95% CI: 0.91-2.04; 
p=0.13).   
 
In the subsample of 225 propensity score-matched patient pairs, the HR value was 
1.73 (95% CI: 1.30-2.28, p<0.001), indicating that the patients initiating dialysis 
with PD had a higher risk of death than those initiating dialysis with HD. The 































Table 5.1. Patient characteristics at dialysis initiation 
 No. of patients  
 HD (n=641) PD (n=230) p-value 
Demographic    
Age at diagnosis (y) 58.2±12.1 64.3±12.3 <0.001 
    ≤65-year-old 454 (70.8%) 115 (50.0%) <0.001 
    >65-year-old 187 (29.2%) 115 (50.0%)  
    ≤60-year-old 358 (55.9%) 73 (31.7%) <0.001 
    >60-year-old 283 (44.1%) 157 (68.3%)  
Gender (n)   <0.01 
    Male  358 (55.8%) 98 (42.6%)  
    Female  283 (44.2%) 132 (57.4%)  
Ethnicity (n)   <0.01 
    Chinese  344 (53.7%) 152 (66.1%)  
    Malay  211 (32.9%) 58 (25.2%)  
    Indian & other 86 (13.4%) 20 (8.7%)  
Socioeconomic status (housing 
type) (n) 
    0.56 
    Lower (public residence) 594 (92.7%) 210 (91.3%)  
    Higher (private residence)  47 (7.3%) 20 (8.7%)  
Co-morbidity    
Diabetes mellitus (%) 426 (66.5%) 172 (74.8%) 0.02 
Hypertension (%) 587 (91.6%) 219 (95.2%) 0.08 
Cardiovascular disease (%) 288 (44.9%) 132 (57.4%) 0.001 
Hyperlipidemia (%) 145 (22.6%) 58 (25.2%) 0.47 
Laboratory tests    
Left ventricular ejection fraction 
(LVEF)  
55.5±13.6 53.3±15.5 0.04 
Haemoglobin level (g/dL) 9.06±1.56 9.60±1.60 <0.001 
Serum albumin level (g/L) 32.2±5.93 34.3±5.82 <0.001 
Phosphate level (mmol/L) 2.00±0.76 1.85±0.82 <0.01 
Parathyroid hormone (PTH) 
(pmol/L) 
31.3±28.8 29.4±24.6 0.38 
Alkaline phosphatase (ALP) 
(U/L) 
96.7±65.4 91.0±49.7 0.23 
Calcium level (mmol/L) 2.20±0.33 2.20±0.28 0.95 
Urate level (μmol/L) 526.4±163.0 538.5±165.5 0.34 
Urea level (mmol/L) 31.38±12.20 30.28±13.10 0.25 
eGFR (ml/min/1.73m2) 7.25±4.24 8.63±5.63 <0.001 




         
                                            Figure 5.1a.                                                                                   Figure 5.1b. 
  Figure 5.1. Kaplan-Meier survival curves by initial modality from day 90, using the entire cohort (Fig. 1a, HD: 641, PD: 230) 
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Table 5.2. Hazard ratios for risk of death for patients initiating PD compared 
with those initiating HD at 5-year follow-up  
Risk factor HR 95 % CI p-value 
PD modality 2.08 1.67-2.59 <0.001 
Age group (>65 years) 1.85 1.50-2.27 <0.001 
Diabetes mellitus (DM) 1.54 1.20-1.99 0.001 
Cardiovascular disease (CVD) 2.06 1.65-2.56 <0.001 




Figure 5.2. Hazard ratios for risk of death for patients initiating PD 
compared with those initiating HD and 95% confidence intervals using 




In subgroup analyses, the higher risk of death in patients starting dialysis with PD 
was observed in old patients without DM, young patients with DM, and old 
patients with DM during the 5 years of follow-up (Figure 5.3); however, among 
175 young patients without DM (HD: 147, PD: 28), the risk of death did not differ 
between patients treated initially with PD and those treated initially with HD 
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for subgroups defined by age and CVD (Figure 5.4). Patients initiating PD had 
significantly higher risk of death in all groups except for 320 young patients 





Figure 5.3. Hazard ratio for risk of death during 5-year follow-up for 
patients initiating PD compared with those initiating HD and 95% 


























































Figure 5.4. Hazard ratio for risk of death during 5-year follow-up for 
patients initiating PD compared with those initiating HD and 95% 





In this study, we found that the survival outcomes may not differ between patients 
starting dialysis in the modality of PD and HD during the first year of treatment, 
but in the long term, the risk of death was significantly higher in patients initiating 
dialysis with PD. We also found that young (≤65-year-old) patients without 
diabetes mellitus or cardiovascular disease might benefit more from PD than HD.  
 
Previous studies comparing the mortality of patients on PD and HD have shown 
varying results  (Heaf, Lokkegaard et al. 2002, Termorshuizen, Korevaar et al. 
2003, Jaar, Coresh et al. 2005, Liem, Wong et al. 2007, Huang, Cheng et al. 2008, 














































Luijtgaarden, Noordzij et al. 2011, Chang, Hsu et al. 2012, Kim, Kim et al. 2014). 
Several studies showed a higher risk of death for patients with PD after the first 
few years of treatment (Termorshuizen, Korevaar et al. 2003, Jaar, Coresh et al. 
2005, McDonald, Marshall et al. 2009, Kim, Kim et al. 2014), consistent with our 
findings, while some previous studies using either large-scale registry data or 
prospective cohort studies have revealed either better survival on PD in the first 
period on dialysis (Heaf, Lokkegaard et al. 2002, van de Luijtgaarden, Noordzij et 
al. 2011) or comparable outcomes between the two treatment groups (Liem, 
Wong et al. 2007, Huang, Cheng et al. 2008, Weinhandl, Foley et al. 2010, Chang, 
Hsu et al. 2012). 
 
The differing findings for the relative survival outcomes of the two dialysis 
modalities in the literature may be explained by several reasons. Firstly, ethnic 
difference is one possibility (Noordzij and Jager 2014). For example, diabetes 
mellitus is more common in Asian than Caucasian dialysis patients (Frankenfield, 
Ramirez et al. 2003, Norris and Agodoa 2005). The prevalence of diabetes 
mellitus was about 70% in this study and 50% in a Korean study which also found 
disadvantaged survival outcomes in PD patients (Kim, Kim et al. 2014). In 
contrast, the prevalence of diabetes mellitus in Western dialysis patients ranged 
from 20% to 45% (Heaf, Lokkegaard et al. 2002, Jaar, Coresh et al. 2005, Liem, 
Wong et al. 2007, Mehrotra, Chiu et al. 2011, Yeates, Zhu et al. 2012). In addition, 
it was hypothesized that some Asian patient populations may be more likely to 




develop diabetes or worsened hyperglycemia during PD treatment because of the 
glucose-containing dialysis fluid (Noordzij and Jager 2014).  
 
Secondly, the variation in quality of PD may contribute. Factors such as 
peritoneal catheters and dialysis fluids used may affect the efficiency and quality 
of dialysis services (Noordzij and Jager 2014). Additionally, PD is monitored by 
the patient him/herself or a family member, and PD patients go to visit their 
health care providers infrequently. As a result, infections and complications may 
be less recognized and timely attended in patients undergoing PD than those 
undergoing HD in dialysis centres (Jaar, Coresh et al. 2005).  
 
Thirdly, the differences may be due to selection bias. Nephrologists may tend to 
recommend PD to patients who have poor prognosis due to weak cardiac function 
(Shahab, Khanna et al. 2006), especially those with poor performance status, i.e. 
assisted activities of daily living or unable to ambulate, which would have 
precluded them from HD (Choo JCJ 2012). The better outcomes of HD may also 
be due to patients’ better economic status. Patients in better economic status may 
prefer HD because they are less concerned about the loss of productivity due to 
the treatment (Tan, Chan et al. 2005, Pacheco, Saffie et al. 2007).  
 
It is not surprising that PD may perform similarly or better in young patients 
without diabetes mellitus or cardiovascular diseases than HD since consistent 
results have been reported in many previous studies (Vonesh, Snyder et al. 2004, 




Jaar, Coresh et al. 2005, Huang, Cheng et al. 2008, Kim, Kim et al. 2014). For 
example, the survival outcome of PD and HD was found to be comparable for 
non-diabetic patients under 55 years in Taiwan (Huang, Cheng et al. 2008). PD 
may confer a survival advantage to young and healthier patients due to better 
preservation of residual renal function compared to those undergoing HD (Vonesh, 
Snyder et al. 2004), and therefore has been suggested to be largely used in the 
young healthier patients, particularly in countries where the PD utilization rate is 
low (Mehrotra, Chiu et al. 2011). Moreover, PD has been shown to have 
advantages in patient satisfaction and quality of life (Molsted, Prescott et al. 2007, 
Yang, Griva et al. 2015). For example, a previous study of dialysis patients in 
Singapore (Yang, Griva et al. 2015) showed that patients undergoing PD 
perceived less burden of kidney disease and dialysis than those undergoing HD. 
Given the relatively low costs of PD and comparable outcomes, promoting PD in 
these subgroups is likely to lead to cost-effective care. As the survival advantage 
of PD in the young healthier patients in our study is not certain, further 
investigation is warranted.   
 
The limitations of the study should not be overlooked. First, because of the lack of 
randomized controlled clinical trials, such observational study could only provide 
information on the effectiveness of dialysis modalities instead of causality 
between dialysis modality and mortality. Second, despite the efforts made to 
adjust for socio-demographic and clinical characteristics, there may be 
unmeasured differences between HD and PD patients, which might lead to excess 




baseline risk for PD patients. Previous studies have shown that in countries where 
older and sicker patients are preferentially considered for PD (McDonald, 
Marshall et al. 2009), patients treated with PD have a higher risk of death than 
those treated with HD after adjusting for covariates; while in countries 
demographic and comorbidity data was comparable in both groups of patients, the 
disadvantage of PD was not observed. Third, the vascular access type of HD 
patients was not available. HD vascular access type was reported to be strongly 
associated with the prognosis of patients (Polkinghorne, McDonald et al. 2004), 
and thus comparisons of HD and PD should include such information whenever 
possible. Last, the data used here was from a single-centre study; it may not 
reflect the dialysis outcomes in other study sites. In view of these drawbacks, 
caution should be exercised in generalizing the results until further studies could 
confirm the findings.  
 
CONCLUSION  
In conclusion, the survival outcomes were similar between patients starting 
dialysis with PD and HD during the first year of dialysis but there was a survival 
advantage of patients who initiated HD during 5 years of follow-up. Survival 
outcomes may not differ between the two dialysis modalities in young and 
healthier patients and further work is needed to evaluate the possible survival 













Cost-effectiveness of Haemodialysis and Peritoneal Dialysis 
 in Patients with End-stage Renal Disease (ESRD) in Singapore 
 





Because of the growing number of patients with chronic kidney disease, 
hypertension, and diabetes mellitus, the number of patients with end-stage renal 
disease (ESRD) requiring renal replacement therapy (RRT), either kidney 
transplantation (TX) or chronic dialysis, is vastly increasing (Klarenbach and 
Manns 2009). By the end of 2010, the number of ESRD patients globally was 
estimated to be 2.6 million and continued to increase at a 6-7% growth rate 
(Grassmann, Gioberge et al. 2005, Fresenius 2010). Among those patients, 77% 
were undergoing chronic dialysis and 23% living with a functional transplant 
(Grassmann, Gioberge et al. 2005). Transplantation leads to longest survival, best 
health-related quality of life (HRQOL) and is most cost-effective for ESRD 
patients (Laupacis, Keown et al. 1996, Oniscu, Brown et al. 2005). However, due 
to the shortage of organ donors and the aging of the ESRD population who may 
not be suitable for transplantation, haemodialysis (HD) or peritoneal dialysis (PD) 
is the common treatment for ESRD. HD is usually performed by the patient in a 
dialysis centre. PD has two main options, either with manual exchange of dialysis 
fluid (continuous ambulatory peritoneal dialysis [CAPD]) or with automated 
exchange of dialysis fluid at night (automated peritoneal dialysis [APD]).  
 
Worldwide, the highly growing ESRD patient population results in expanding 
costs of RRT programmes. In most developed countries, about 2% of the national 
healthcare budgets is spent caring for ESRD patients, despite the fact that less 
than 0.1% of the total population has ESRD (De Vecchi, Dratwa et al. 1999). At 




the end of 2010, the aggregate costs of treating ESRD would have exceeded $1 
trillion US dollar (Lysaght 2002). In Singapore, the incidence and prevalence of 
ESRD is high and projected to increase rapidly due to aging and the high 
prevalence of diabetes (Tan, Chan et al. 2005). According to Ministry of Health 
Singapore, the direct cost of dialysis provision and its associated services was 
about Singapore dollar (S$)36,000 (US$21,000) per patient per year in 2000 and 
the total expenditure was estimated to increase by 2.5-fold from S$90 million in 
1999 to S$241 million in 2010 (Tan, Chan et al. 2005).  
 
Given the heavy health burden and budget constraints, the assessment of the cost-
effectiveness of treatments for ESRD is critical for current and future healthcare 
sustainability. Economic evaluations about the dialysis modalities have been 
performed in many countries (de Wit, Ramsteijn et al. 1998, Kirby and Vale 2001, 
Sennfalt, Magnusson et al. 2002, Hooi, Lim et al. 2005, Pacheco, Saffie et al. 
2007, Salonen, Reina et al. 2007, Teerawattananon, Mugford et al. 2007, 
Kontodimopoulos and Niakas 2008, Berger, Edelsberg et al. 2009, Haller, Gutjahr 
et al. 2011, Villa, Fernandez-Ortiz et al. 2012). While majority of these studies 
reported the consistent conclusion that PD was more cost-effective than HD, one 
UK study concluded that HD may be more cost-effective than CAPD (Kirby and 
Vale 2001) and the studies done in Malaysia and Chile showed the cost-
effectiveness of both modalities were nearly equal (Hooi, Lim et al. 2005, 
Pacheco, Saffie et al. 2007). Due to the differences in dialysis service provision 




and financing systems between these countries and Singapore, any of these 
findings may not be generalizable to the local setting.  
 
Hence, in this study, we performed a cost-effectiveness analysis of three dialysis 





HD, CAPD and APD were compared using the same Markov model (Figure 6.1). 
The base case was a hypothetical cohort of 60-year-old non-diabetic patients with 
newly diagnosed ESRD and no contraindictions to any of the modalities. 
 
 
Figure 6.1. Structure of the Markov model 
 
 




The health states in the model included: dialysis, TX and death. In Cycle 0, all 
patients are in the “dialysis” state, which could be HD, CAPD or APD. All 
patients could remain in the “modality” or make a transition to another health 
state in a subsequent cycle. Patients cannot change their modalities in any cycle. 
A cycle length of 1 year was used.  
 
Evaluated outcomes included costs, quality-adjusted life years (QALYs) and 
survival over a 10-year time horizon. The main outcome measure was incremental 
costs effectiveness ratio (ICER). The cost-effectiveness of the alternatives 
depends upon the value of the ICER and on whether the incremental of outcome 
is positive or negative. The willingness-to-pay (WTP) was set as Singapore’s 
average per-capita gross domestic product (GDP) from 2005 to 2014 (Statistics 
2015), i.e. S$60,000 per QALY, which was USD$43,700 per QALY according to 
purchasing power parities (Statistics 2015). For an intervention which is more 
effective than its comparator, it would be considered cost-effective if the ICER is 
less than S$60,000 per QALY in this study. 
 
The model development and analyses were performed using Microsoft Excel 
2010 (Microsoft Inc., USA).  
 
Costs 
The cost analysis was carried out from the societal perspective, so direct (medical 
and nonmedical) and indirect costs were both considered. All cost data is present 




in 2015 S$. Costs per year were calculated for each state of health in the model. 
Costs were discounted at an annual rate of 3%. The estimation methods for 
different cost components are described as below. 
 
Direct medical costs 
Vascular (HD) and peritoneal (PD) accesses 
The costs of access surgery were obtained from the Division of Nephrology, 
National University Hospital (NUH), Singapore, by consulting the renal 
administrator. The costs of creating arteriovenous fistula for HD patients were 
estimated to be S$4000. Regarding the peritoneal access costs, the total costs of 
laboratory tests before surgery and surgical procedure were considered and the 
sum costs of PD access were estimated to be S$2501.  
 
Training 
Based on NUH data, PD patients are required to attend a 4.5-day training session 
before undergoing routine dialysis. The total costs of PD training were estimated 
as S$700 including costs of training, consultation and consumables used.  
 
Depreciated infrastructure  
HD is mainly performed in the dialysis centres affiliated to a voluntary welfare 
organization, e.g. National Kidney Foundation (NKF) Singapore. According to 
NKF Financial Statements 2014, the depreciation of property, plant and 
equipment was estimated to be S$3,527,000 for 2672 HD patients undergoing 




dialysis in all affiliated centres. So the depreciated infrastructure costs per patient 
per year were estimated at S$1320. 
 
HD treatment session 
The costs of the HD treatment for private patients in NKF dialysis centres are 
considered to cover the consumables costs, medical staff costs and other overhead 
costs. The costs are S$185 per patient per session. Assuming dialysis 3 times per 
week per patient, the annual dialysis costs per patient were S$28860.  
 
PD treatment session 
According to Ministry of Health Singapore 2006 report about kidney disease, the 
costs of APD were 500 S$ more than the costs of CAPD. Costs of CAPD are 
based on NUH's charges of S$1594 per month in 2013. We assumed the costs of 
APD were still 500 more than CAPD in 2013. The costs have been adjusted for 
inflation (using the average inflation index of 2.80% from 1962 to 2014 in 
Singapore) and the annual costs of CAPD and APD per patient were estimated to 
be S$20214 and S$26555, respectively. 
 
Medication 
The costs of erythropoietin (EPO) were taken into account and the data was 
obtained from the Ministry of Health. The yearly medication costs per patient 
were estimated to be S$2661 for HD and S$1717 for PD in 2013 and have been 
inflated to be S$2812 for HD and S$1814 for PD in 2015.  




Outpatient clinics follow-up and laboratory tests 
Data from NUH was used to estimate these costs. HD patients are required to see 
their specialists once every 6 months, and assuming they also need to do 
laboratory test, the costs of outpatient clinics and laboratory tests were estimated 
to be S$3161. PD patients are required to see their specialists once every 3 
months, and assuming they need to do laboratory test every 6 months, the costs of 
outpatient clinics and laboratory tests were estimated to be S$3391. 
 
Hospitalization 
Data of an incident dialysis patient cohort from NUH hospitalized for any reason 
was used to estimate the length of stay (LOS) of dialysis patients. As the dataset 
failed to differentiate CAPD and APD, we assumed that the LOS was the same 
for both groups. The costs of hospitalization were based on the average daily B1 
general ward cost of the Singapore General Hospital and NUH multiplying by the 
LOS. The LOS was estimated based on the time after dialysis initiation and 
assumed to be constant from the 5
th
 year onwards. Detailed information of the 
costs of hospitalization is shown in Table 6.1. 
 
Death 
Based on the hospitalization data, we found that patients who died within the year 
would have a longer LOS than those who were still alive at the end of that year. 
HD had average 20 days more and PD had 16 days more. So we considered these 
as costs of death. 





Data about the costs of transplantation surgery and the immunosuppressant 
medication was obtained from the Ministry of Health. The transplantation surgery 
was estimated to be S$55423. The costs of medication including follow-up 
outpatient clinics and laboratory tests were estimated to be S$13926 and these 
was considered as annual costs of patients who got transplantation.  
 
Direct nonmedical costs 
Transportation 
Based on the assumption that patients were living in an area with a diameter of 10 
km and they would go to hospital for specialist clinic by taxi and go to dialysis 
centre by public transportation, we used data in Land and Transportation 
Authority, i.e. S$10 of one-way fare of 10km distance by taxi and 2.5 by public 
transportation, to estimate the costs of transportation.  
 
Indirect costs 
Indirect productivity costs were calculated from both days of work missed due to 
routine outpatient clinics and dialysis sessions, and additional hospitalization days. 
The costs were calculated based on 80% of the time required for respective 
dialysis treatment and LOS, multiplied against the 2014 average national wage in 
Singapore (median monthly income 3770). Considering the retirement age of 62 
in Singapore, we assumed that patients aged 62 years more would not incur loss 
of productivity cost. The costs for each of the items described above are 




summarized in Table 6.1. The costs of each modality by year are reported in 
Table 6.2 and this data was entered into the Markov model. 
 
 
Table 6.1. Summary of costs for each of the items per patient for the dialysis 
modalities considered in the base case analysis 
  Cost (Singapore dollar S$) 
  HD CAPD APD TX 
Direct medical costs      
  one-off costs at beginning      
    access costs  4,000 2,501 2,501 55,423 
    PD training   / 700 700 / 
recurrent annual costs      
    depreciated infrastructure costs  1,320 / / / 
    annual dialysis costs  28,860 20,214 26,555 / 
    erythropoietin (EPO)    2,812 1,815 1,815 / 
    outpatient clinics and laboratory tests  3,161 3,391 3,391 13,926 
    hospitalization Year 1 5,417 4,239 4,239 / 
 Year 2 2,604 2,312 2,312 / 
 Year 3 2,318 2,652 2,652 / 
 Year 4 2,360 2,515 2,515 / 
 Year 5 2,553 2,884 2,884 / 
  death  4,199 3,359 3,359 2,100 
Direct non-medical costs      
    transportation  765 74 74 / 
Indirect costs       
    loss of productivity due to dialysis  7,267 3,839 3,839 / 
    loss of productivity due to hospitalization Year 1 3,538 2,769 2,769 / 




Table 6.2. Summary of costs per patient per year for the dialysis modalities 
considered in the base case analysis 
Year 
Cost (Singapore dollar S$) 
HD CAPD APD 
Pre-dialysis 4,000 3,201 3,201 
Year 1 55,931 39,499 45,840 
Year 2 51,402 36,212 42,553 
Year 3 40,950 29,872 36,212 
Year 4 40,983 29,678 36,019 
Year 5 and above 41,107 30,403 36,744 
 
 





Data from Singapore Renal Registry 2009 and the survival analysis of an incident 
ESRD patient cohort described in Chapter 5 was used to estimate the transition 
probabilities. Due to the lack of survival data for CAPD and APD patients, we 
assumed that the mortality rates were the same for both PD modalities. The 
survival results from Chapter 5 showed that the rates would change as the 
duration of dialysis increased, so the cycle-specific mortality rates were computed 
for HD and PD. For the purpose of this study, it was assumed that mortality rates 
and transition probabilities were constant from the 5
th
 year onwards.  
 
Outcomes 
To calculate QALYs, health utilities for different health states were multiplied by 
the time spent in each state. To obtain the utility scores of different health states in 
the Markov model, a patient survey was conducted and the method was described 
in Chapter 4. Because the survey was cross-sectional, we assumed that the 
patient’s health utility was constant during dialysis. The EuroQol 5-dimension 
(EQ-5D) health utility scores derived from the survey were used as the base case 
estimates and shown in Table 6.3, while the utility values for TX were from a 
meta-analysis conducted by Wyld (Wyld, Morton et al. 2012). The QALYs were 








One-way sensitivity analysis 
One-way sensitivity analyses were performed on all parameters included in the 
model. The plausible ranges of transition probabilities and health utilities were 
determined a priori in Table 6.3, and because of the greater uncertainty regarding 
cost estimates, a wider range of 50% to 200% of the base case values was used. In 
addition, the health utilities measured by the Short Form 6-dimension (SF-6D) in 
Chapter 4 were also used as part of one-way sensitivity analysis. 
 
Probabilistic sensitivity analysis 
To evaluate the impact of uncertainty on all the parameter values simultaneously, 
a probabilistic sensitivity analysis was performed using a Monte Carlo simulation 
with 1,000 iterations. We assumed a log-normal distribution for event rates, a 
gamma distribution for costs and a beta distribution for utilities. The 














Table 6.3. Summary of transition probabilities and health utilities variables 
for the dialysis modalities considered in the base case analysis 
Variable  Value Range  Source /notes 
Probabilities     
 HD-death (1st year) 0.031 0.006-0.083 
Survival analysis in Chapter 5 
 HD-death (2nd year) 0.033 0.005-0.113 
 HD-death (3rd year) 0.028 0.008-0.050 
 HD-death (4th year) 0.020 0.003-0.060 
 HD-death (5th year) 0.040 0.0004-0.125 
 PD-death (1st year) 0.076 0.024-0.159 
 PD-death (2nd year) 0.093 0.007-0.249 
 PD-death (3rd year) 0.147 0.005-0.293 
 PD-death (4th year) 0.082 0.009-0.176 
 PD-death (5th year) 0.111 0.011-0.279 
 HD/PD-TX 0.018 
NA Singapore Renal Registry 2009 
 TX-Death 0.021 
Health utilities     
 HD 0.635 0.549-0.734 
Patient survey in Chapter 4  CAPD 0.587 0.538-0.651 
 APD 0.629 0.544-0.739 





























Table 6.4. Parameterization of distributions for the probabilistic sensitivity 
analysis in the base case analysis 
Parameter  Distribution (parameters) 
Costs  Gamma (alpha, beta) 
 HD-pre 1, 4000 
 HD-1st year 1, 53140 
 HD-2nd year 1, 48490 
 HD-3rd year 1, 39236 
 HD-4th year 1, 39278 
 HD-5th year 1, 39471 
 HD-death 1, 4199 
 CAPD-pre 1, 3201 
 CAPD-1st year 1, 36341 
 CAPD -2nd year 1, 33155 
 CAPD -3rd year 1, 28146 
 CAPD -4th year 1, 28009 
 CAPD -5th year 1, 28379 
 CAPD-death 1, 3359 
 APD-pre 1, 3201 
 APD-1st year 1, 42682 
 APD -2nd year 1, 39495 
 APD -3rd year 1, 34486 
 APD -4th year 1, 34350 
 APD -5th year 1, 34720 
 APD-death 1, 3359 
 TX-surgery 1, 55423 
 TX-annual 1, 13926 
 TX-death 1, 2100 
Transition probabilities  Lognormal (u, sigma) 
 HD-death (1st year) 0.031, 1.406 
 HD-death (2nd year) 0.033, 1.511 
 HD-death (3rd year) 0.028, 1.263 
 HD-death (4th year) 0.020, 1.498 
 HD-death (5th year) 0.040, 2.052 
 PD-death (1st year) 0.076, 1.275 
 PD-death (2nd year) 0.093, 1.571 
 PD-death (3rd year) 0.147, 1.696 
 PD-death (4th year) 0.082, 1.457 
 PD-death (5th year) 0.110, 1.513 
 HD/PD-TX - 
 TX-Death - 
Health utilities  Beta (alpha, beta) 
 HD 44.34, 25.49 
 CAPD 97.35, 68.61 
 APD 44.54, 26.24 
 TX 58.51, 27.53 




Analysis of high risk group (60-year-old diabetic patients) 
Variables used in the 60-year-old diabetic patients were estimated using the same 
method as described above for the base case. This group of patients had longer 
LOS, higher mortality rates and lower health utilities than the base case. Data is 
shown in Table 6.5 and Table 6.6. Other variables were the same as the base case. 
Similar one-way sensitivity analyses and probabilistic sensitivity analyses were 
also applied for this high risk group by using the corresponding ranges in Table 
6.6 and distributions in Table 6.7. 
 
Table 6.5. Hospitalization-related costs in the high risk group 
  Cost (Singapore dollar S$) 
Modality  Variable Year 1 Year 2 Year 3 Year 4 Year 5 
HD Costs of hospitalization 7105 4365 4031 4065 4189 
 Loss of productivity due 
to hospitalization 
4640 2851 / / / 
PD Costs of hospitalization 6150 4162 4378 4185 4909 
 Loss of productivity due 
to hospitalization 
























Table 6.6. Summary of transition probabilities and health utilities variables 
for the high risk group 
Variable  Value Range  Source /notes 
Probabilities     
 HD-death (1st year) 0.067 0.008-0.225 
Survival analysis in Chapter 5 
 HD-death (2nd year) 0.083 0.006-0.243 
 HD-death (3rd year) 0.079 0.004-0.242 
 HD-death (4th year) 0.040 0.003-0.139 
 HD-death (5th year) 0.086 0.001-0.193 
 PD-death (1st year) 0.088 0.012-0.210 
 PD-death (2nd year) 0.136 0.016-0.394 
 PD-death (3rd year) 0.204 0.015-0.491 
 PD-death (4th year) 0.187 0.015-0.544 
 PD-death (5th year) 0.252 0.008-0.776 
 HD/PD-TX 0.018 
NA Singapore Renal Registry 2009 
 TX-Death 0.021 
Health utilities     
 HD 0.599 0.509-0.698 
Patient survey in Chapter 4  CAPD 0.577 0.473-0.659 
 APD 0.588 0.493-0.686 





























Table 6.7. Parameterization of distributions for the probabilistic sensitivity 
analysis for the high risk group 
Parameter  Distribution (parameters) 
Costs  Gamma (alpha, beta) 
 HD-pre 1, 4000 
 HD-1st year 1, 55931 
 HD-2nd year 1, 51402 
 HD-3rd year 1, 40950 
 HD-4th year 1, 40983 
 HD-5th year 1, 41107 
 HD-death 1, 4199 
 CAPD-pre 1, 3201 
 CAPD-1st year 1, 39499 
 CAPD -2nd year 1, 36212 
 CAPD -3rd year 1, 29871 
 CAPD -4th year 1, 29678 
 CAPD -5th year 1, 30403 
 CAPD-death 1, 3359 
 APD-pre 1, 3201 
 APD-1st year 1, 45840 
 APD -2nd year 1, 42553 
 APD -3rd year 1, 36212 
 APD -4th year 1, 36019 
 APD -5th year 1, 36744 
 APD-death 1, 3359 
 TX-surgery 1, 55423 
 TX-annual 1, 13926 
 TX-death 1, 2100 
Transition probabilities  Lognormal (u, sigma) 
 HD-death (1st year) 0.067, 1.524 
 HD-death (2nd year) 0.083, 1.646  
 HD-death (3rd year) 0.079, 1.697 
 HD-death (4th year) 0.040, 1.626 
 HD-death (5th year) 0.086, 1.933 
 PD-death (1st year) 0.088, 1.439 
 PD-death (2nd year) 0.136, 1.509 
 PD-death (3rd year) 0.204, 1.559 
 PD-death (4th year) 0.187, 1.580 
 PD-death (5th year) 0.252, 1.794 
 HD/PD-TX - 
 TX-Death - 
Health utilities  Beta (alpha, beta) 
 HD 41.68, 27.90 
 CAPD 53.04, 38.85 
 APD 47.83, 33.48 
 TX 58.11, 34.13 





Two scenarios were considered for model assumptions that are not adequately 
studied so far. Scenario 1 was to increase time horizon to 20 years by assuming 
that PD patients would switch to HD at the beginning of the 11
th
 year and HD 
patients would stay the same modality for 20 years. Scenario 2 was to assume 
one-time switch between HD and PD during the 10-year time horizon. The 
probability of modality switch at 6% was from the UK renal registry (Mowatt, 
Vale et al. 2003) because such data was not available in Singapore.    
 
RESULTS  
Base case analysis 
The base case analysis showed that the QALYs were 3.27 with CAPD, 3.48 with 
APD and 4.69 with HD (Table 6.8). The total costs were S$169,872 for CAPD, 
201,509 for APD and 306,827 for HD. The ICER of APD versus CAPD was 
S$150,652 per QALY and the ICER of HD versus CAPD was 96,447. Both 
exceeded S$60,000. CAPD and HD had extended dominance over APD, as shown 
in Figure 6.2. Therefore, CAPD was cost-effective in the base case scenario.  
 
Table 6.8. Projected costs, QALYs and ICERs in base case analysis 
Modality  Cost (S$) Effectiveness 
(QALY) 
Incremental cost per QALY gained (S$/QALY)  
(CAPD as comparator) 
CAPD 169,872 3.27 NA 
APD 201,509 3.48 150,652 (dominated by extended dominance) 









Figure 6.2. Base case results shown on the cost-effectiveness plane 
 
 
One-way sensitivity analyses 
One-way sensitivity analyses showed that several parameters influenced the cost-
effectiveness of HD versus CAPD. The model was most sensitive to the utility for 
HD. However, when the values of all model parameters were varied across 
plausible ranges, the ICER values of HD versus CAPD remained more than 
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Probabilistic sensitivity analysis 
The uncertainty of the cost-effectiveness results for a range of WTP threshold is 
presented as cost-effectiveness acceptability curves in Figure 6.4. The 
acceptability curves for base case showed that the probabilities of CAPD, APD 
and HD being the optimal treatment strategy were 36.2%, 33.2% and 30.6%, 
respectively, using a WTP threshold of $60,000 per QALY. But if the threshold 
increased to $70,000, the probability of HD being cost-effective was more than 




Figure 6.4. Cost-effectiveness acceptability curves in the base case analysis. The 




















































Analysis of high risk group 
The analysis of high risk group showed that the QALYs were 2.50 with CAPD, 
2.54 with APD and 3.69 with HD (Table 6.9). The total costs were S$144,972 for 
CAPD, 169,282 for APD and 271,446 for HD. The ICER of APD versus CAPD 
was S$607,750 per QALY and the ICER of HD versus CAPD was 106,281. Both 
exceeded S$60,000. CAPD and HD had extended dominance over APD as shown 
in Figure 6.5. Therefore, CAPD was also cost-effective in the high risk group.  
 
Table 6.9. Projected costs, QALYs and ICERs in high risk group 
Modality  Cost (S$) Effectiveness 
(QALY) 
Incremental cost per QALY gained (S$/QALY)  
(CAPD as comparator) 
CAPD 144,972 2.50 NA 
APD 169,282 2.54 607,750 (dominated by extended dominance) 

































One-way sensitivity analysis 
Similarly, the model was most sensitive to the utility for HD. When the values of 
all model parameters were varied across plausible ranges, no substantial influence 
on the ICER of HD versus CAPD was found and the varied ICER values 
remained more than S$60,000 per QALY, indicating CAPD was more cost-
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Probabilistic sensitivity analysis 
The probabilities of CAPD, APD and HD being the optimal treatment strategy 
were 44.9%, 30.5% and 24.6%, respectively, using a WTP threshold of S$60,000 
per QALY. If the threshold increased to S$100,000, the probability of HD was 
more than that of CAPD, i.e. 37.4% versus 37.0% (Figure 6.7). 
Figure 6.7. Cost-effectiveness acceptability curves in the high risk group. The 




When setting the time horizon to 20 years and assuming PD patients would switch 
to HD after 10 years, ICERs remained higher than 60,000 per QALY. When 
assuming a one-time switch between HD and PD, results of the base case and 
high risk group analyses were similar. Starting dialysis with CAPD was still the 
















































Table 6.10. Cost-effectiveness results of scenario analyses for the base case 




Incremental cost per QALY gained 
(S$/QALY) 
Scenario 1: 20-year time horizon  
  CAPD  235,235 4.53 - 
  APD  266,872 4.74 150,652 
  HD  434,351 7.14 76,290 
Scenario 2: one-time switch between HD to PD  
  CAPD 191,922 3.50 - 
  APD 216,788 3.67 146,271 
  HD (CAPD) 282,078 4.46 93,913 
  HD (APD) 289,629 4.46 101,778 
 
 
Table 6.11. Cost-effectiveness results of scenario analyses for the high risk 
group 




Incremental cost per QALY gained 
(S$/QALY) 
Scenario 1: 20-year time horizon  
  CAPD  164,310 2.90 - 
  APD  188,620 2.94 607.750 
  HD  343,087 4.97 86,366 
Scenario 2: one-time switch between HD to PD  
  CAPD 167,381 2.71 - 
  APD 187,250 2.74 662,300 
  HD (CAPD) 251,860 3.50 106,935 




To the best of our knowledge, this is the first cost-utility analysis of dialysis 
therapies for patients with ESRD in Singapore. The findings of this study may be 
used to inform policy and clinical decision making and also provide an important 
reference for future cost-effectiveness studies of ESRD treatments in Singapore as 
well as other countries with similar healthcare settings.  
 




In both base case (60-year-old non-diabetic patients) and high risk group (60-
year-old diabetic patients) analyses, CAPD as an initial treatment is more cost-
effective than HD and APD, using a WTP threshold of S$60, 000 per QALY. The 
robustness of the results was further confirmed by the sensitivity analysis and 
scenario analysis. There is increasing pressure on dialysis services because of the 
growing number of people who are receiving dialysis. It appears that PD is less 
costly than HD, so an increase in this modality of dialysis could mitigate the 
anticipated total cost increases of dialysis to the society. Currently, PD is used in 
only a very small proportion of cases, especially in Singapore, where less than 14% 
of the incident ESRD patients aged 30-59 years old initiated their dialysis on PD 
in 2009 (Choong 2012). The results suggest that CAPD may be the optimal 
treatment for patients who have no contraindication to any dialysis modalities, so 
some interventions, e.g., patient education and clinicians’ recommendation, could 
be developed to identify and guide appropriate patients to CAPD treatment. 
 
Although there is no agreed willingness-to-pay threshold for adopting health 
technologies in Singapore, the threshold of one GDP per capita is commonly used, 
as recommended by World Health Organization (WHO). In this study, the 
acceptability curves showed how the cost-effectiveness of the three dialysis 
modalities would change if different thresholds were used. Unless decision-
makers are willing to pay S$70,000 per QALY for the base case and S$100,000 
per QALY for high risk group, “HD first” would be the optimal choice for ESRD 
patients.  




The findings of this study were consistent with most previous cost-effectiveness 
analyses, which showed HD was more costly, more effective, but less cost-
effective than CAPD (de Wit, Ramsteijn et al. 1998, Sennfalt, Magnusson et al. 
2002, Salonen, Reina et al. 2007, Teerawattananon, Mugford et al. 2007, 
Kontodimopoulos and Niakas 2008, Berger, Edelsberg et al. 2009, Haller, Gutjahr 
et al. 2011, Villa, Fernandez-Ortiz et al. 2012). However, these studies reported 
cost-effectiveness ratios (CERs) of different dialysis modalities or ICERs 
compared with palliative care, instead of ICER of HD versus CAPD, so we could 
not directly compare the ICER values. Nevertheless, one UK study (Kirby and 
Vale 2001) using data from literature concluded that it may be cost-effective to 
manage patients starting on dialysis with HD than with CAPD. This contradicting 
finding could possibly be explained by the fact that only direct medical costs of 
each treatment were included in that study, but indirect costs resulted from loss of 
productivity would be much higher in HD than in PD (Pacheco, Saffie et al. 2007). 
The authors also attributed the cost-effectiveness of HD to the fact that patients 
undergoing CAPD would incur more costs by switching to HD than a HD patient 
would by switching to CAPD. But in our study, we assumed no transfer between 
modalities, so costs associated with modality switch were not included in analyses. 
What’s more, our results were conflicting with the results of the studies in 
Malaysia and Chile (Hooi, Lim et al. 2005, Pacheco, Saffie et al. 2007), both of 
which reported no difference in cost-effectiveness between HD and PD. This may 
be due to the lower cost of human resources in these countries (Blake 2002). HD 
is labor intensive than PD and so its costs is determined more by staff salaries 




than is the case for PD (Blake 2002). So the clear cost advantage seen for PD 
would be more apparent in the developed countries than in developing countries.  
 
This study was based on various sources of data and assumptions. Therefore, 
these results are subject to considerable uncertainty of parameter estimation. 
Although great efforts were made to identify the best data available, there are 
some limitations in this study. 
 
A detailed “bottom-up” costing exercise was used to derive information from one 
restructured hospital and the NKF dialysis centre. However, as there was no 
individual-level data available, we could not quantify the uncertainty surrounding 
the costs of each treatment and explore its impact on ICER. In this study, a 50% 
to 200% plausible range was assumed to all cost items, which may not fully 
reflect the uncertainty in costs. Also, due to the unavailability of data, the costs of 
hospitalization were estimated only in terms of the bed charges of inpatient care; 
costs of procedures, drugs, and other tests were not considered. However, because 
the study focused on the incremental cost-effectiveness of therapies, the results 
should not have been significantly biased. 
 
Because there is lack of local effectiveness evidence from randomized controlled 
trials or meta-analysis, survival parameters were estimated using data from a 
single-centre observational study of incident dialysis patients with a maximum 
follow-up period of 5 years. It has been recognized that PD patients were older 




and had more comorbid conditions when initiating dialysis than HD patients, 
which would negatively impact the survival outcomes, as a consequence, the 
QALYs associated with PD would be lower and thus the ICER of HD compared 
with PD would be biased in favor of HD. Additionally, the results of APD versus 
CAPD were based on the assumptions of equal survival and same LOS between 
CAPD and APD. Nevertheless, there may be differences in mortality and 
hospitalization between these two PD modalities.  
 
The utility values for dialysis patients were obtained from a cross-sectional study 
of prevalent dialysis patients, which failed to quantify the change of health utility 
during long-term dialysis (Yang, Griva et al. 2015). Using health utilities derived 
from prevalent patients may underestimate the health utility of incident patients at 
the initial period of dialysis since previous studies have shown that there was a 
reverse correlation between duration dialysis and quality of life (Anees, Hameed 
et al. 2011). However, one-way sensitivity analyses showed that only in the base 
case scenario and when the health utility value for HD was higher than 0.770, HD 
would be the optimal choice. The health utility for TX patients was assumed equal 
to the utility of general population, which may be overestimated as previous 
research about TX patients in Singapore reported the HRQOL was slightly lower 
than population norms (Griva, Stygall et al. 2011).  
 
Regarding the model building, first, in the base case, we assumed no transfer 
between dialysis modalities because of the lack of such data. This assumption has 




been tested in the scenario analysis using a switch probability of 6% and the 
results supported the cost-effectiveness of CAPD. In clinical practice in Singapore, 
there may be more PD patients switch to HD than the other direction. So if 
possible, more analyses should be done using local data to draw more valid 
conclusions. Second, transition from TX back to dialysis due to transplantation 
failure was not considered in the model. This was because that no data was 
available for estimating this transition probability in Singapore or the possibly 
increased probability of those patients to get re-transplantation (Rao, Schaubel et 
al. 2006). Because the transplantation rate in Singapore is low, it is unlikely that 
our conclusions would be different if transplantation failure had been modeled in 
this study.  
 
Last, the Markov model was used in this study to simulate the disease progression 
of dialysis patients. Although such model has been widely used in the evaluation 
of healthcare interventions, the Markovian assumption may limit its use in 
modelling this patient population. This assumption means that once a notional 
patient has moved from one state to another, the Markov model will have ‘no 
memory’ regarding where the patient has come from or the timing of that 
transition. For dialysis patients, as mentioned previously, the transitions 
probabilities for those who had transplantation failure or switched from one 
modality to another would have different probabilities of future transitions. 
Modelling such process may be possible by adding additional states to the 
Markov model and incorporating time dependency transition probabilities. But as 




the number of such dependencies increases, the volume of health states required 
to represent the structure becomes unmanageable.  
 
Therefore, discrete event simulation (DES) could be an alternative to the Markov 
technique in modelling the dialysis patients. It is suggested that DES should be 
used when the model structure required to capture all important differences in the 
costs and benefits of alternative technologies requires health states that are so 
numerous as to be unmanageable to implement as a cohort-based Markov model.  
 
There are several advantages of DES. First, the Markov approach is difficult to 
handle the heterogeneity in the characteristics of the population modelled because 
this requires a large number of states. In a DES, individuals are assigned their 
own unique values for the set of characteristics, including memory of all that has 
happed, which could control what happens next to each individual. Second, when 
modelling time-varying probabilities using Markov technique, several tunnel 
states are usually added and this may result in many states when there are many 
conditions over a long duration. The implementation of time-varying event rates 
is straightforward in a DES as time is treated continuously and risks can change 
accordingly. Patients undergoing dialysis usually have some comorbid conditions 
and these conditions would have significant impact on their transition 
probabilities in models, which make the use of DES desirable to provide a more 
realistic representation of the costs and effects of the treatments compared.  
 




But the main challenge of the DES is this model requires more data, especially 
primary and individual-level data.  In this study, due to limited data, a DES could 
not be constructed and an alternative approach of Markov technique was 
implemented using the data available. Future research using DES to simulate this 
patient population is suggested to be undertaken to represent the complex disease 
process if better data sources could be accessible.    
   
CONCLUSION 
In conclusion, this study found that CAPD may be a cost-effective therapy 
compared with HD and APD in patients with ESRD in Singapore. Despite the 
data related to limitations in this model-based study, this finding is potentially 
















A Recapitulation of Major Findings, 











Although a variety of questionnaires have been used to assess the health-related 
quality of life (HRQOL) of patients with end-stage renal disease (ESRD), it is not 
well documented whether these instruments are valid and suitable for ESRD 
patients in Singapore. Hence, a validation study of the disease-specific instrument, 
i.e., the Kidney Disease Quality of Life 36-Item (KDQOL-36), consisting of 
Medical Outcomes Study 12-Item Short Form (SF-12) and kidney disease-
specific items, was first performed in this project. Using data collected in a cross-
sectional survey of haemodialysis (HD) patients, we found the kidney disease 
scales, i.e. symptoms/problems, effects and burden, showed known-groups 
validity and internal consistency reliability. For the generic SF-12 items, a three-
factor model (role, physical and mental functions) fit the data better than the 
‘physical-mental’ structure. Poor fit of the two-factor model for the SF 
instruments has been observed in other studies among Asian populations and the 
three-factor model has been proposed by the instrument developer as a 
substitution of the current two-factor model. Although the generic scales seemed 
to measure slightly different constructs in Asian patients, these results suggested 
that the KDQOL-36 appeared to be reliable and valid and thus could be used to 
measure the HRQOL of Singaporean ESRD patients.  
 
After addressing the issue of using disease-specific HRQOL instruments for 
ESRD patients in Singapore, the logical next step would be to assess generic 
instruments. In order to pave the way to the subsequent economic evaluations, we 




compared the performance of two widely used preference-based HRQOL 
measures, i.e., the EuroQol 5-dimension (EQ-5D) and the Short Form 6-
dimension (SF-6D) index scores among a sample of prevalent dialysis patients 
interviewed using the 5-level EQ-5D (EQ-5D-5L) and KDQOL-36 questionnaires. 
Both EQ-5D-5L and SF-6D demonstrated satisfactory known-groups validity but 
cannot be used interchangeably due to different sensitivity to outcomes and poor 
agreement; EQ-5D score derived from the SF-12 performed similarly as the EQ-
5D score calculated from EQ-5D-5L in quantifying differences between groups of 
patients in differing health status and then both EQ-5D scores might lead to more 
favorable cost-effectiveness results than the SF-6D score when they are used to 
quantify health benefits in economic evaluations.  
 
Based on the findings from the previous studies, the KDQOL-36 was used to 
measure patients’ HRQOL and then we explored the effect of dialysis modality on 
HRQOL and identified the significant factors affecting the HRQOL of this patient 
population using data from two cross-sectional surveys of prevalent dialysis 
patients. We found that dialysis modality has minimal impact on the SF-12 based 
EQ-5D and SF-6D health utility scores of those patients and that clinical 
characteristics are better predictors of HRQOL in dialysis patients than socio-
demographics. This study suggested that more attention should be paid to patients 
with co-morbidity, malnutrition or anemia, as well as younger Chinese in order to 
improve their quality of life.  
 




Whether and how dialysis modalities may influence ESRD patients’ survival is 
another important topic of this project. Using survival data for a maximum of 5 
years from a single-centre cohort of incident dialysis patients and the flexible 
Royston-Parmar parametric models, we compared the survival outcomes of 
patients who started dialysis with HD and PD and in subgroups defined by age, 
diabetes mellitus, and cardiovascular disease. It seemed that the ESRD patients 
who initiated dialysis with HD experienced better survival outcomes than those 
who initiated dialysis with PD in Singapore, although there was no significant 
difference in mortality in the first 12 months after dialysis initiation. We also 
found that PD may be similar to or better than HD in survival outcomes among 
young and healthier patients.  
 
Although HRQOL measured by utility scores did not differ significantly between 
patients undergoing these two dialysis modalities, the better long-term survival of 
HD and the cost advantage of PD suggest that it is necessary to assess the cost-
effectiveness of these treatments.  
 
Therefore, the project moved on to a formal cost-effectiveness analysis. Using 
health utility and secondary local clinical and costs data, a Markov model was 
constructed to compare the costs and QALYs of HD and two PD modalities, i.e., 
continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal 
dialysis (APD). In both base case (60-year-old non-diabetic patients) and high risk 
group (60-year-old diabetic patients) analyses, CAPD and HD had extended 




dominance over APD, and CAPD was found to be cost-effective using a willing-
to-pay (WTP) threshold of Singapore dollar (S$) 60,000 (US$43,000) per QALY. 
The incremental cost-effective ratio (ICER) value of HD versus CAPD was 
S$96,447 per QALY for the base case and 106,281 for the high risk group. 
Probabilistic sensitivity analysis confirmed these results by demonstrating that the 
probability of CAPD being the optimal choice was 36.2% for the base case and 
44.9% for the high risk group at the same WTP threshold. 
 
MAIN CONTRIBUTIONS 
This project has three main contributions to the outcomes and economics research 
in multiethnic Asian patients with ESRD. 
 
First, we validated several HRQOL instruments (KDQOL-36, EQ-5D and SF-6D) 
which can be used among multiethnic ESRD patients in Singapore. This work 
provides a firm basis for the use of these HRQOL measures in future outcomes 
research involving ESRD patients.  
 
Second, the project provided valuable information regarding quality of life and 
survival outcomes of dialysis treatments for ESRD patients in Singapore. 
Knowledge about the risk factors of poor HRQOL and the survival patterns of 
different dialysis modalities could guide the identification of more vulnerable 
ESRD patients and help to develop interventions to improve the effectiveness of 
dialysis services. Some suggestions have been proposed to the local healthcare 




professionals: paying more attention to patients with poorer co-morbidity profiles 
and those with malnutrition or anemia to improve their quality of life; increasing 
the use of PD among the young and healthier patients because of the possible 
survival advantages of PD for them.  
 
Third, this project provided robust results of cost-effectiveness of three available 
dialysis modalities in Singapore. To the best of our knowledge, this is the first 
cost-utility analysis of dialysis treatments for ESRD patients in Singapore. The 
findings of this project would throw some light upon the future policy and clinical 
decision making for dialysis services to ensure sustainability of ESRD care and 
also provide an important reference for future cost-effectiveness studies of ESRD 
treatments in Singapore as well as other countries with similar healthcare setting. 
 
MAIN LIMITATIONS 
The limitations have been discussed in details in the individual chapters. Here are 
the two limitations we would like to emphasize. 
 
First, the EQ-5D health utility score used in Chapter 4 and Chapter 6 was mapped 
from the SF-12 using a scoring algorithm. Although the results from Chapter 3 
have shown that the SF-12 based EQ-5D score performed similarly as the directly 
elicited EQ-5D score from EQ-5D-5L in quantifying known-group differences, it 
is the second best alternative to the direct use of a preference-based measure. 




Second, when estimating the parameters for the economic evaluation models, the 
ideal data source is random controlled trials or meta-analysis evidence. However, 
due to the lack of such data in Singapore, results from cross-sectional and 
observational studies were used to estimate the death probabilities and health 
utilities, which may not reflect the real effectiveness of dialysis modalities.  
 




Based on the findings and limitations obtained from above studies, this project 
raised some new research questions that could be topics of future studies.  
 
A longitudinal-designed study about HRQOL of ESRD patients would allow 
assessment of the responsiveness of HRQOL instruments and what’s more, results 
from such study would provide better estimation of the health utilities to calculate 
the QALYs for the cost-effectiveness analysis.  
 
A detailed analysis of costs of ESRD treatments using individual-level data could 
be performed to accurately evaluate the economic burden of ESRD and further the 
foundation of this field. Future studies comparing the survival outcomes of 
patients undergoing different dialysis modalities are needed to provide high-
quality evidence on effectiveness of dialysis options and thus inform better choice 




between alternative choices. Using the discrete event simulation to model the 
dialysis patients would better represent the complex disease process and increase 
the credibility of the results.    
 
Apart from the effectiveness and cost-effectiveness, there are other factors which 
would influence patients’ choice of dialysis modality, such as knowledge of 
dialysis and family support. Studies regarding patient preference would enable 
patients’ involvement in medical decision making and provide more information 
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